14

CORRECTED VERSION

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 27947WOP00	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/AU00/00363	International Filing Date *(day/month/year)* 26 April 2000	Priority Date *(day/month/year)* 21 April 1999

International Patent Classification (IPC) or national classification and IPC

Int. Cl. [7] G01N 33/574

Applicant

[THE UNIVERSITY OF SYDNEY et al] BIOSCEPTRE PTY LTD

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

[X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 4 sheet(s).

3. This report contains indications relating to the following items:

I	[X]	Basis of the report
II	[ ]	Priority
III	[ ]	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	[ ]	Lack of unity of invention
V	[X]	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	[ ]	Certain documents cited
VII	[ ]	Certain defects in the international application
VIII	[ ]	Certain observations on the international application

Date of submission of the demand	Date of completion of the report
31 October 2000	1 August 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer **DAVID HENNESSY** Telephone No. (02) 6283 2255

CORRECTED VERSION

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00363

I. Basis of the report

1. With regard to the **elements** of the international application:*

☐ the international application as originally filed.

☒ the description, pages **1-7, 9-27,** as originally filed,
pages , filed with the demand,
pages **8,** received on **16 July 2001** with the letter of **12 July 2001.**

☒ the claims, pages **30-33,** as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages **28, 29,** received on **16 July 2001** with the letter of **12 July 2001.**

☒ the drawings, pages **1/9, 2/9, 4/9-9/9,** as originally filed,
pages **3/9,** received on **16 July 2001** with the letter of **12 July 2001,**
pages , received on with the letter of .

☐ the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report*

CORRECTED VERSION

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00363

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-56	YES
	Claims		NO
Inventive step (IS)	Claims	1-56	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-56	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Citations: Claims 1-56

Nawa, G. et al. (1999) BRITISH JOURNAL OF CANCER, vol. 80 (8), 1185-1189;

Wurl, P. et al (1998) ONCOGENE, vol 16 (9), 1183-1185;

EP 1006186 A (OTSUKA PHARMACEUTICAL CO. LTD.), 20 October 1998.

Novelty (N) and Inventive Step (IS): Claims 1-56

Nawa et al. discuss the pattern of P2XM expression in tumours, and suggests that an insufficiency of normal P2XM could contribute to development and/or progression of the majority of soft-tissue tumours. Date of publication of this document is 2 June 1999 according to documents supplied by the applicants. This is 43 days after the priority date. Because the priority is not in question, the citation is not considered to deprive the claims of inventive step or novelty because it was published too late.

Wurl et al. links Mdm2 and p53 in the prognosis of soft tissue sarcoma neoplasm. While there is a link between P2XM and Mdm, the citation does not utilise the detection of P2X receptors in the diagnosis of neoplasm. Consequently the claims are novel and inventive over the citation.

EP 1006186 discloses the identification of target genes for p53 or p53 induced genes. The p53 inducible gene disclosed belongs to the P2X family encoded ATP gated ion channel. The citation does not disclose utilising the P2X gene for detecting of neoplasms. The claims are novel and inventive over the citation.

Industrial Applicability (IA): Claims 1-56

All claims are considered to have industrial applicability.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00363

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. [7]: G01N 33/574

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Chem. Abs., WPIDS, Medline: purinergic recepetors, sarcoma, neoplasm, cancer, tumour, tumor, purinergic ion channel, P2X, marker, profile, expression, diagnosis

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Nawa, G., *et al* , 1999. BRITISH JOURNAL OF CANCER, 80(8): 1185-89. Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours. - see whole document	1
X	Wurl, P., *et al* , 1998. ONCOGENE, 16(9): 1183-85. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. - see whole document	1

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 July 2000	15/08/00

Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaustralia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer
ISOBEL TYSON
Telephone N : (02) 6283 2563

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00363

C (Continuation). **DOCUMENTS CONSIDERED T BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AU 64184/98 (OTSUKA PHARMACEUTICAL CO., LTD.), 20 October 1998 - see abstract	1
A	Urano, T. *et al* , 1997. CANCER RESEARCH, 57: 3281-87. Cloning of P2XM, a novel human P2X receptor gene regulated by p53. - see whole document	1
A	Höpfner, M., *et al* , 1998. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 251: 811-17. Expression of functional P_2-purinergic receptors in primary cultures of human colorectal carcinoma cells. - see whole document	1

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00363

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
AU	64184/98	WO	9842835	EP	1006186	JP	10262681
							END OF ANNEX

PATENT COOPERATION TREATY

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

T :

BALDWIN SHELSTON WATERS
Level 21
60 Margaret Street
SYDNEY NSW 2000

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Applicant's or agent's file reference
27947WOP00

IMPORTANT NOTIFICATION

International Application No.	International Filing Date	Priority Date
PCT/AU00/00363	26 April 2000	21 April 1999

Applicant
THE UNIVERSITY OF SYDNEY et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translations to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide

Name and mailing address of the IPEA/AU	Authorized officer
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	DAVID HENNESSY Telephone No. (02) 6283 2255

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 27947WOP00	**FOR FURTHER ACTION**	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/AU00/00363	International Filing Date *(day/month/year)* 26 April 2000	Priority Date *(day/month/year)* 21 April 1999
International Patent Classification (IPC) or national classification and IPC Int. Cl.[7] G01N 33/574		
Applicant THE UNIVERSITY OF SYDNEY et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

   [X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 4 sheet(s).

3. This report contains indications relating to the following items:

I	[X]	Basis of the report
II	[ ]	Priority
III	[ ]	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	[ ]	Lack of unity of invention
V	[X]	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	[ ]	Certain documents cited
VII	[ ]	Certain defects in the international application
VIII	[ ]	Certain observations on the international application

Date of submission of the demand 31 October 2000	Date of completion of the report 1 August 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer **DAVID HENNESSY** Telephone No. (02) 6283 2255

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Internati nal application No.
PCT/AU00/00363

I. Basis of the report

1. With regard to the elements of the international application:*

☐ the international application as originally filed.

☒ the description, pages 1-7, 9-27, as originally filed,
pages , filed with the demand,
pages 8, received on 16 July 2001 with the letter of 12 July 2001.

☒ the claims, pages 30-33, as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages 28, 29, received on 16 July 2001 with the letter of 12 July 2001.

☒ the drawings, pages 1/9, 2/9, 4/9-9/9, as originally filed,
pages 3/9, received on 16 July 2001 with the letter of 12 July 2001,
pages , received on with the letter of .

☐ the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (s me of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report*

PATENT COOPERATION TREATY

Fr m the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

BALDWIN SHELSTON WATERS
Level 21
60 Margaret Street
SYDNEY NSW 2000

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing (day/month/year) 10 AUG 2001

Applicant's or agent's file reference
27947WOP00

IMPORTANT NOTIFICATION

International Application No.	International Filing Date	Priority Date
PCT/AU00/00363	26 April 2000	21 April 1999

Applicant
THE UNIVERSITY OF SYDNEY et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translations to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide

Name and mailing address of the IPEA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaustralia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

DAVID HENNESSY
Telephone No. (02) 6283 2255

CORRECTED VERSION

CORRECTED VERSION

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 27947WOP00	**FOR FURTHER ACTION**	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. **PCT/AU00/00363**	International Filing Date *(day/month/year)* 26 April 2000	Priority Date *(day/month/year)* 21 April 1999
International Patent Classification (IPC) or national classification and IPC Int. Cl.[7] G01N 33/574		
Applicant THE UNIVERSITY OF SYDNEY et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

   [X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 4 sheet(s).

3. This report contains indications relating to the following items:

I	[X]	Basis of the report
II	[ ]	Priority
III	[ ]	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	[ ]	Lack of unity of invention
V	[X]	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	[ ]	Certain documents cited
VII	[ ]	Certain defects in the international application
VIII	[ ]	Certain observations on the international application

Date of submission of the demand 31 October 2000	Date of completion of the report 1 August 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer **DAVID HENNESSY** Telephone No. (02) 6283 2255

CORRECTED VERSION

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00363

I. Basis of the report

1. With regard to the elements of the international application:*

☐ the international application as originally filed.

☒ the description, pages 1-7, 9-27, as originally filed,
pages , filed with the demand,
pages 8, received on 16 July 2001 with the letter of 12 July 2001.

☒ the claims, pages 30-33, as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages 28, 29, received on 16 July 2001 with the letter of 12 July 2001.

☒ the drawings, pages 1/9, 2/9, 4/9-9/9, as originally filed,
pages 3/9, received on 16 July 2001 with the letter of 12 July 2001,
pages , received on with the letter of .

☐ the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report*

CORRECTED VERSION

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00363

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-56	YES
	Claims		NO
Inventive step (IS)	Claims	1-56	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-56	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Citations: Claims 1-56

Nawa, G. et al. (1999) BRITISH JOURNAL OF CANCER, vol. 80 (8), 1185-1189;

Wurl, P. et al (1998) ONCOGENE, vol 16 (9), 1183-1185;

EP 1006186 A (OTSUKA PHARMACEUTICAL CO. LTD.), 20 October 1998.

Novelty (N) and Inventive Step (IS): Claims 1-56

Nawa et al. discuss the pattern of P2XM expression in tumours, and suggests that an insufficiency of normal P2XM could contribute to development and/or progression of the majority of soft-tissue tumours. Date of publication of this document is 2 June 1999 according to documents supplied by the applicants. This is 43 days after the priority date. Because the priority is not in question, the citation is not considered to deprive the claims of inventive step or novelty because it was published too late.

Wurl et al. links Mdm2 and p53 in the prognosis of soft tissue sarcoma neoplasm. While there is a link between P2XM and Mdm, the citation does not utilise the detection of P2X receptors in the diagnosis of neoplasm. Consequently the claims are novel and inventive over the citation.

EP 1006186 discloses the identification of target genes for p53 or p53 induced genes. The p53 inducible gene disclosed belongs to the P2X family encoded ATP gated ion channel. The citation does not disclose utilising the P2X gene for detecting of neoplasms. The claims are novel and inventive over the citation.

Industrial Applicability (IA): Claims 1-56

All claims are considered to have industrial applicability.

CORRECTED VERSION

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 27947WOP00	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/AU00/00363	International Filing Date *(day/month/year)* 26 April 2000	Priority Date *(day/month/year)* 21 April 1999
International Patent Classification (IPC) or national classification and IPC Int. Cl. [7] G01N 33/574		
Applicant THE UNIVERSITY OF SYDNEY et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

   [X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 4 sheet(s).

3. This report contains indications relating to the following items:

I	[X]	Basis of the report
II	[ ]	Priority
III	[ ]	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	[ ]	Lack of unity of invention
V	[X]	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	[ ]	Certain documents cited
VII	[ ]	Certain defects in the international application
VIII	[ ]	Certain observations on the international application

Date of submission of the demand 31 October 2000	Date of completion of the report 1 August 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile N . (02) 6285 3929	Authorized Officer DAVID HENNESSY Telephone No. (02) 6283 2255

CORRECTED VERSION

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00363

I. Basis of the report

1. With regard to the elements of the international application:*

- [ ] the international application as originally filed.
- [X] the description, pages 1-7, 9-27, as originally filed,
  pages , filed with the demand,
  pages 8, received on 16 July 2001 with the letter of 12 July 2001.
- [X] the claims, pages 30-33, as originally filed,
  pages , as amended (together with any statement) under Article 19,
  pages , filed with the demand,
  pages 28, 29, received on 16 July 2001 with the letter of 12 July 2001.
- [X] the drawings, pages 1/9, 2/9, 4/9-9/9, as originally filed,
  pages 3/9, received on 16 July 2001 with the letter of 12 July 2001,
  pages , received on with the letter of .
- [ ] the sequence listing part of the description:
  pages , as originally filed
  pages , filed with the demand
  pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:

- [ ] the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- [ ] the language of publication of the international application (under Rule 48.3(b)).
- [ ] the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- [ ] contained in the international application in written form.
- [ ] filed together with the international application in computer readable form.
- [ ] furnished subsequently to this Authority in written form.
- [ ] furnished subsequently to this Authority in computer readable form.
- [ ] The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- [ ] The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. [ ] The amendments have resulted in the cancellation of:

- [ ] the description, pages
- [ ] the claims, Nos.
- [ ] the drawings, sheets/fig.

5. [ ] This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental B x (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report*

CORRECTED VERSION

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application N .
PCT/AU00/00363

V.) **Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Claims	1-56	YES
	Claims		NO
Inventive step (IS)	Claims	1-56	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-56	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

Citations: Claims 1-56

Nawa, G. et al. (1999) BRITISH JOURNAL OF CANCER, vol. 80 (8), 1185-1189;

Wurl, P. et al (1998) ONCOGENE, vol 16 (9), 1183-1185;

EP 1006186 A (OTSUKA PHARMACEUTICAL CO. LTD.), 20 October 1998.

Novelty (N) and Inventive Step (IS): Claims 1-56

Nawa et al. discuss the pattern of P2XM expression in tumours, and suggests that an insufficiency of normal P2XM could contribute to development and/or progression of the majority of soft-tissue tumours. Date of publication of this document is 2 June 1999 according to documents supplied by the applicants. This is 43 days after the priority date. Because the priority is not in question, the citation is not considered to deprive the claims of inventive step or novelty because it was published too late.

Wurl et al. links Mdm2 and p53 in the prognosis of soft tissue sarcoma neoplasm. While there is a link between P2XM and Mdm, the citation does not utilise the detection of P2X receptors in the diagnosis of neoplasm. Consequently the claims are novel and inventive over the citation.

EP 1006186 discloses the identification of target genes for p53 or p53 induced genes. The p53 inducible gene disclosed belongs to the P2X family encoded ATP gated ion channel. The citation does not disclose utilising the P2X gene for detecting of neoplasms. The claims are novel and inventive over the citation.

Industrial Applicability (IA): Claims 1-56

All claims are considered to have industrial applicability.

PCT/AU00/00363
Received 12 July 2001

CORRECTED VERSION



Fig 3
The following figure shows an example of P2X1 labelling in normal breast (right) and a substantial down-regulation in breast tumour tissue (left).

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

COMMUNICATION OF
INTERNATIONAL APPLICATIONS

(PCT Article 20)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as designated Office

Date of mailing:
19 December 2000 (19.12.00)

The International Bureau transmits herewith copies of the international applications having the following international application numbers and international publication numbers:

International application no.:	International publication no.:
PCT/AU00/00363	

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

BALDWIN SHELSTON WATERS
60 Margaret Street
Sydney, NSW 2000
AUSTRALIE

Date of mailing (day/month/year)	IMPORTANT NOTIFICATION
26 October 2001 (26.10.01)	
Applicant's or agent's file reference	
27947WOP00	
International application No.	**International filing date** (day/month/year)
PCT/AU00/00363	26 April 2000 (26.04.00)

1. The following indications appeared on record concerning:

[X] the applicant [ ] the inventor [ ] the agent [ ] the common representative

Name and Address

THE UNIVERSITY OF SYDNEY
Business Liaison Office, John
Woolley Building A20
Cnr Manning Road & Western Avenue
Sydney, NSW 2006
Australia

State of Nationality: AU
State of Residence: AU
Telephone No.: (612) 9351 4000
Facsimile No.: (612) 9351 3636
Teleprinter No.:

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[ ] the person [X] the name [X] the address [ ] the nationality [ ] the residence

Name and Address

BIOSCEPTRE PTY LTD
Level 10, 26 O'Connell Street
Sydney, NSW 2000
Australia

State of Nationality: AU
State of Residence: AU
Telephone No.: (612) 9351 4000
Facsimile No.: (612) 9351 3636
Teleprinter No.:

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

[X] the receiving Office
[ ] the International Searching Authority
[ ] the International Preliminary Examining Authority
[ ] the designated Offices concerned
[X] the elected Offices concerned
[ ] other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer V. Gross (Fax 338.87.40)
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

Copy for the elected Office (EO/US)

P. NT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

COMMUNICATION IN CASES FOR WHICH NO OTHER FORM IS APPLICABLE

To:
BALDWIN SHELSTON WATERS
60 Margaret Street
Sydney, NSW 2000
AUSTRALIE

Date of mailing (*day/month/year*) 15 December 2000 (15.12.00)	
Applicant's or agent's file reference 27947WOP00	**REPLY DUE** see paragraph 1 below
International application No. PCT/AU00/00363	International filing date (*day/month/year*) 26 April 2000 (26.04.00)
Applicant THE UNIVERSITY OF SYDNEY	

1. ☐ REPLY DUE within _____ months/days from the above date of mailing

☐ NO REPLY DUE, however, see below

☒ IMPORTANT COMMUNICATION

☐ INFORMATION ONLY

2. COMMUNICATION:

The International Bureau regrets to inform the applicant that, due to an error in our computer system, the above identified international application has not been published promptly after the expiration of 18 months from the priority date, as provided in PCT Article 21(2)(a).

International publication will now take place on 25 January 2001 (25.01.01)

Meanwhile, the International Bureau will communicate a copy of the international application to each designated Office, in accordance with PCT Article 20.

A copy of this notification has been sent to the receiving Office RO/AU and all designated Offices.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer
Beate Giffo-Schmitt

Telephone No. (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing: 25 January 2001 (25.01.01)	
International application No.: PCT/AU00/00363	Applicant's or agent's file reference: 27947WOP00
International filing date: 26 April 2000 (26.04.00)	Priority date: 21 April 1999 (21.04.99)
Applicant: SLATER, Michael et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International preliminary Examining Authority on:

31 October 2000 (31.10.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

URGENT

FROM THE RECEIVING OFFICE

To:

The International Bureau of WIPO
34, chemin des Colombettes
1211, Geneva 20
Switzerland

PCT

REQUEST FOR THE RECORDING OF A CHANGE
(PCT Rule 92*bis*.1)

Date of Mailing *(day/month/year)*	
18 October 2001	
International Application No.	**International Filing Date** *(day/month/year)*
PCT/AU00/00363	26 April 2000

1. The following indications appear on record concerning:

[X] the applicant [ ] the inventor [ ] the agent [ ] the common representative

Name and address	State of Nationality* / State of Residence*
The University of Sydney Business Liaison Office, John Woolley Building A20 Cnr Manning Road & Western Avenue SYDNEY NSW 2006 Australia	Telephone No: (612) 9351 4000 Facsimile No. (612) 9351 3636 Teleprinter No.

2. This receiving Office hereby requests the International Bureau to record the following change in::

[ ] the person [X] the name [X] the address [ ] the nationality* [ ] the residence*

Name and address	State of Nationality* / State of Residence*
BIOSCEPTRE PTY LTD Level 10 26 Oconnell Street SYDNEY NSW 2000 Australia	Telephone No. Facsimile No. Teleprinter No.

3. Further observations, if necessary: **Original documents will be forwarded upon receipt by this Office.**

* To be indicated for a change concerning the applicant

Name and mailing address of the receiving Offic	Authorised Officer
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606 AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No.: (02) 6285 3929	(Mrs) Anne HAMMETT Telephone No.: (02) 6283 2503

Form PCT/RO/113 (July 1992)

(1)

P NT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

REC'D 18 AUG 2000
WIPO PCT

Applicant's or agent's file reference	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
27947WOP00		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/AU00/00363	26 April 2000	21 April 1999
Applicant: The University of Sydney et al		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (See Box II).

4. With regard to the **title,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**

☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure

☐ because this figure better characterizes the invention

☒ None of the figures

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 27947WOP00	**FOR FURTHER ACTION**	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. **PCT/AU00/00363**	International Filing Date *(day/month/year)* 26 April 2000	Priority Date *(day/month/year)* 21 April 1999

International Patent Classification (IPC) or national classification and IPC

Int. Cl. [7] G01N 33/574

Applicant

THE UNIVERSITY OF SYDNEY et al

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

[X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of **4** sheet(s).

3. This report contains indications relating to the following items:

I	[X]	Basis of the report
II	[ ]	Priority
III	[ ]	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	[ ]	Lack of unity of invention
V	[X]	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	[ ]	Certain documents cited
VII	[ ]	Certain defects in the international application
VIII	[ ]	Certain observations on the international application

Date of submission of the demand	Date of completion of the report
31 October 2000	1 August 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer **DAVID HENNESSY** Telephone No. (02) 6283 2255

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00363

I. Basis of the report

1. With regard to the **elements** of the international application:*

☐ the international application as originally filed.

☒ the description, pages **1-7, 9-27,** as originally filed,
pages , filed with the demand,
pages **8,** received on **16 July 2001** with the letter of **12 July 2001.**

☒ the claims, pages **30-33,** as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages **28, 29,** received on **16 July 2001** with the letter of **12 July 2001.**

☒ the drawings, pages **1/9, 2/9, 4/9-9/9,** as originally filed,
pages **3/9,** received on **16 July 2001** with the letter of **12 July 2001,**
pages , received on with the letter of .

☐ the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages

☐ the claims, Nos.

☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report*

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	**1-56**	**YES**
	Claims		**NO**
Inventive step (IS)	Claims	**1-56**	**YES**
	Claims		**NO**
Industrial applicability (IA)	Claims	**1-56**	**YES**
	Claims		**NO**

2. Citations and explanations (Rule 70.7)

Citations: Claims 1-56

Nawa, G. et al. (1999) BRITISH JOURNAL OF CANCER, vol. 80 (8), 1185-1189;

Wurl, P. et al (1998) ONCOGENE, vol 16 (9), 1183-1185;

EP 1006186 A (OTSUKA PHARMACEUTICAL CO. LTD.), 20 October 1998.

Novelty (N) and Inventive Step (IS): Claims 1-56

Nawa et al. discuss the pattern of P2XM expression in tumours, and suggests that an insufficiency of normal P2XM could contribute to development and/or progression of the majority of soft-tissue tumours. Date of publication of this document is 2 June 1999 according to documents supplied by the applicants. This is 43 days after the priority date. Because the priority is not in question, the citation is not considered to deprive the claims of inventive step or novelty because it was published too late.

Wurl et al. links Mdm2 and p53 in the prognosis of soft tissue sarcoma neoplasm. While there is a link between P2XM and Mdm, the citation does not utilise the detection of P2X receptors in the diagnosis of neoplasm. Consequently the claims are novel and inventive over the citation.

EP 1006186 discloses the identification of target genes for p53 or p53 induced genes. The p53 inducible gene disclosed belongs to the P2X family encoded ATP gated ion channel. The citation does not disclose utilising the P2X gene for detecting of neoplasms. The claims are novel and inventive over the citation.

Industrial Applicability (IA): Claims 1-56

All claims are considered to have industrial applicability.

tissue from a prostate having benign prostate hyperplasia, is diagnostic of the presence of prostate cancer.

According to a fourth aspect, the present invention provides a method of diagnosing breast cancer in a subject comprising detecting the expression profile of $P2X_2$ or $P2X_3$, purinergic receptors in breast cells and/or tissue from the subject using $P2X_2$ or $P2X_3$, antibody respectively, wherein a decrease in the intensity of the P2X purinergic receptor expression profile in the breast cells and/or tissue from the breast of a normal subject, is diagnostic of the presence of breast cancer.

According to a fifth aspect, the invention provides use of P2X purinergic receptor antibody reagent to stage and/or diagnose a pre-neoplastic and/or neoplastic state in a mammalian subject.

According to a sixth aspect, the invention provides use of P2X purinergic receptor antibody reagent to determine the aetiology of carcinogenesis in a mammalian subject.

According to a seventh aspect, the invention provides an isolate mammalian cell or tissue sample complexed with a P2X purinergic receptor-specific antibody reagent.

According to an eight aspect, the invention provides a kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising means for detecting P2X purinergic receptor expression profile in a sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method of staging and/or diagnosing pre-neoplastic and/or neoplastic states in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from said mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

2. A method of determining the aetiology of carcinogenesis in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with predetermined expression profile of normal cells and/or tissue.

3. A method according to claim 1 or claim 2 wherein the mammal is a human.

4. A method according to any one of claims 1 to 3 wherein the cells are prostate tissue cells.

5. A method according to any one of claims 1 to 3 wherein the cells are breast tissue cells.

6. A method according to any one of claims 1 to 4 wherein the cells are obtained by biopsy.

7. A method according to claim 5 wherein the cells are obtained by biopsy.

8. A method according to any one of claims 1 to 4 wherein the cells are obtained from a body fluid, from digital rectal examination exudate and/or from semen.

9. A method according to any one of claims 1 to 8 wherein detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent.

10. A method according to any one of claims 1 to 4 or 6, 8 or 9 wherein the detection of the P2X purinergic receptor expression profile comprises use of a P2X antibody reagent specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_6$ or $P2X_7$.

11. A method according to claim 5 or claim 7 wherein the detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent specific for $P2X_2$ or $P2X_3$.

12. A method of diagnosing prostate cancer in a subject, comprising detecting the expression profile of $P2X_1$, $P2X_2$, $P2X_3$ and/or $P2X_7$ purinergic receptors in prostate cells and/or tissue from the subject using $P2X_1$, $P2X_2$, $P2X_3$ and/or $P2X_7$ antibody respectively, wherein an increase in the intensity of the P2X purinergic receptor expression profile in the prostate cells and/or tissue, compared to the expression profile of prostate cells and/or tissue from a prostate having benign prostate hyperplasia, is diagnostic of the presence of prostate cancer.

13. A method of diagnosing breast cancer in a subject comprising detecting the expression profile of $P2X_2$ or $P2X_3$ purinergic receptors in breast cells and/or tissue from the subject using $P2X_2$ or $P2X_3$ antibody respectively, wherein a decrease in the intensity of the P2X purinergic receptor expression profile in the breast cells and/or tissue compared to the expression profile of breast cells and/or tissue from the breast of a normal subject, is diagnostic of the presence of breast cancer.

14. A method according to any one of claims 9 to 13 wherein the antibody reagent comprises a polyclonal antiserum.

15. A method according to any one of claims 9 to 13 wherein the antibody reagent comprises a monoclonal antiserum.

16. A method according to any one of claims 9 to 14, wherein the antibody reagent is a suite of polyclonal antibodies.

17. A method according to any one of claims 9 to 13 or 15, wherein the antibody reagent is a suite of monoclonal antibodies.

Fig 3

The following figure shows an example of P2X1 labeling in normal breast (right) and a substantial down-regulation in breast tumour tissue (left).

RECORD COPY PCT

PCT/AU 00 / 00363

For receiving Office use only

PCT/AU 00 / 00363
International Application No.

26 APR 2000 (26.04.00)
International Filing Date

Australian Patent Office
PCT INTERNATIONAL APPLICATION
Name of receiving Office and "PCT International Application"

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty

Applicant's or agent's file reference *(if desired) (12 characters maximum)* **27947WOP00**

Box No. I **TITLE OF INVENTION**

A METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS

Box No. II **APPLICANT**

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

The University of Sydney
Business Liaison Office, John Woolley Building A20
Cnr Manning Road & Western Avenue
Sydney, NSW 2006
Australia

☐ This person is also inventor.

Telephone No.
(612) 9351 4000

Facsimile No.
(612) 9351 3636

Teleprinter No.

State *(that is, country)* of nationality:
AU

State *(that is, country)* of residence:
AU

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III **FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)**

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

SLATER, Michael
Flat 3/511 Burwood Road
Belmore, NSW 2192
Australia

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only *(if this check-box is marked, do not fill in below.)*

State *(that is, country)* of nationality:
AU

State *(that is, country)* of residence:
AU

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV **AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

BALDWIN SHELSTON WATERS
60 MARGARET STREET
SYDNEY NSW 2000
AUSTRALIA

Telephone No.
(612) 9777 1111

Facsimile No.
(612) 9241 4666

Teleprinter No:

☐ **Address for correspondence:** Mark this check-box where no agent or common representative is/has been appointed and the space above

PCT/AU 00/00363

Continuation of Box No III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet is not to be included in the request.

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.*) **BARDEN, Julian** **48 Mawarra Crescent** **Marsfield, NSW 2122** **Australia**	This person is: ☐ applicant only ☒ applicant and inventor ☐ inventor only (*if this check-box is marked, do not fill in below.*)
State (*that is, country*) of nationality: **AU**	State (*that is, country*) of residence: **AU**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.*)	This person is: ☐ applicant only ☐ applicant and inventor ☐ inventor only (*if this check-box is marked, do not fill in below.*)
State (*that is, country*) of nationality:	State (*that is, country*) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.*)	This person is: ☐ applicant only ☐ applicant and inventor ☐ inventor only (*if this check-box is marked, do not fill in below.*)
State (*that is, country*) of nationality:	State (*that is, country*) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (*Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.*)	This person is: ☐ applicant only ☐ applicant and inventor ☐ inventor only (*if this check-box is marked, do not fill in below.*)
State (*that is, country*) of nationality:	State (*that is, country*) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) *(mark the applicable check-boxes; at least one must be marked)*:

Regional Patent

☒ **AP** **ARIPO Patent:** **GH** Ghana, **GM** Gambia, **KE** Kenya, **LS** Lesotho, **MW** Malawi, **SD** Sudan, **SL** Sierra Leone, **SZ** Swaziland, **TZ** United Republic of Tanzania, **UG** Uganda, **ZW** Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT

☒ **EA** **Eurasian Patent:** **AM** Armenia, **AZ** Azerbaijan, **BY** Belarus, **KG** Kyrgyzstan, **KZ** Kazakhstan, **MD** Republic of Moldova, **RU** Russian Federation, **TJ** Tajikistan, **TM** Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT

☒ **EP** **European Patent:** **AT** Austria, **BE** Belgium, **CH and LI** Switzerland and Liechtenstein, **CY** Cyprus, **DE** Germany, **DK** Denmark, **ES** Spain, **FI** Finland, **FR** France, **GB** United Kingdom, **GR** Greece, **IE** Ireland, **IT** Italy, **LU** Luxembourg, **MC** Monaco, **NL** Netherlands, **PT** Portugal, **SE** Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT

☒ **OA** **OAPI Patent:** **BF** Burkina Faso, **BJ** Benin, **CF** Central African Republic, **CG** Congo, **CI** Côte d'Ivoire, **CM** Cameroon, **GA** Gabon, **GN** Guinea, **GW** Guinea-Bissau, **ML** Mali, **MR** Mauritania, **NE** Niger, **SN** Senegal, **TD** Chad, **TG** Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT *(if other kind of protection or treatment desired, specify on dotted line)* .....

National Patent *(if other kind of protection or treatment desired, specify on dotted line)*:

☒ **AE** United Arab Emirates
☒ **AL** Albania
☒ **AM** Armenia
☒ **AT** Austria
☒ **AU** Australia
☒ **AZ** Azerbaijan
☒ **BA** Bosnia and Herzegovina
☒ **BB** Barbados
☒ **BG** Bulgaria
☒ **BR** Brazil
☒ **BY** Belarus
☒ **CA** Canada
☒ **CH and LI** Switzerland and Liechtenstein
☒ **CN** China
☒ **CR** Costa Rica
☒ **CU** Cuba
☒ **CZ** Czech Republic
☒ **DE** Germany
☒ **DK** Denmark
☒ **DM** Dominica
☒ **EE** Estonia
☒ **ES** Spain
☒ **FI** Finland
☒ **GB** United Kingdom
☒ **GD** Grenada
☒ **GE** Georgia
☒ **GH** Ghana
☒ **GM** Gambia
☒ **HR** Croatia
☒ **HU** Hungary
☒ **ID** Indonesia
☒ **IL** Israel
☒ **IN** India
☒ **IS** Iceland
☒ **JP** Japan
☒ **KE** Kenya
☒ **KG** Kyrgyzstan
☒ **KP** Democratic People's Republic of Korea
☒ **KR** Republic of Korea
☒ **KZ** Kazakhstan
☒ **LC** Saint Lucia
☒ **LK** Sri Lanka
☒ **LR** Liberia
☒ **LS** Lesotho
☒ **LT** Lithuania
☒ **LU** Luxembourg
☒ **LV** Latvia
☒ **MA** Morocco
☒ **MD** Republic of Moldova
☒ **MG** Madagascar
☒ **MK** The former Yugoslav Republic of Macedonia
☒ **MN** Mongolia
☒ **MW** Malawi
☒ **MX** Mexico
☒ **NO** Norway
☒ **NZ** New Zealand
☒ **PL** Poland
☒ **PT** Portugal
☒ **RO** Romania
☒ **RU** Russian Federation
☒ **SD** Sudan
☒ **SE** Sweden
☒ **SG** Singapore
☒ **SI** Slovenia
☒ **SK** Slovakia
☒ **SL** Sierra Leone
☒ **TJ** Tajikistan
☒ **TM** Turkmenistan
☒ **TR** Turkey
☒ **TT** Trinidad and Tobago
☒ **TZ** United Republic of Tanzania
☒ **UA** Ukraine
☒ **UG** Uganda
☒ **US** United States of America
☒ **UZ** Uzbekistan
☒ **VN** Viet Nam
☒ **YU** Yugoslavia
☒ **ZA** South Africa
☒ **ZW** Zimbabwe

Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet:

☒ DZ Algeria▲
☒ AG Antigua and Barbuda▲

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. *(Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)*

PCT/AU 00 / 00363

Box No. VI PRIORITY CLAIM ☒ Further priority claims indicated in the Supplemental Box.

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is: national application: country	regional application:* regional Office	international application: receiving Office)
item (1) 21 April 1999 (21.04.99)	PP9911	AU		
item (2)				
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) *(only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office)* identified above as item(s): (1)

* *Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii). See Supplemental Box.*

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) *(if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):*

ISA /

Request to use results of earlier search; reference to that search *(if an earlier search has been carried out by or requested from the International Searching Authority):*

Date *(date/month/year)* Number Country *(or regional Office)*

Box No. VIII CHECK LIST; LANGUAGE OF FILING

This international application contains the following **number of sheets**:

request	:	4
Description (excluding sequence listing part)	:	27
claims	:	6
abstract	:	1
drawings	:	5
Sequence listing part of description	:	
Total number of sheets	:	43

This international application is **accompanied by** the item(s) marked below:

1. ☒ fee calculation sheet
2. ☐ separate signed power of attorney
3. ☐ copy of general power of attorney; reference number, if any:
4. ☐ statement explaining lack of signature
5. ☐ priority document(s) identified in Box No. VI as item(s):
6. ☐ translation of international application into (language):
7. ☐ separate indications concerning deposited microorganism or other biological material
8. ☐ nucleotide and/or amino acid sequence listing in computer readable form
9. ☐ other *(other specify)*:

Figure of the drawings which should accompany the abstract: -

Language of filing of the international application: **English**

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

Ivan Rajkovic
BALDWIN SHELSTON WATERS

For receiving Office use only

1. Date of actual receipt of the purported international application: 26 APR 2000 (26.04.00)
2. Drawings: ☒ received: ☐ not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:
4. Date of timely receipt of the required corrections under PCT Article 11(2):
5. International Searching Authority specified by the applicant: ISA/
6. ☐ Transmittal of search copy delayed until search fee is paid

For International Bureau use only

Date of receipt of the record copy by the International Bureau: 10 MAY 2000 (10.05.00)

See Notes to the request form

A METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS

TECHNICAL FIELD

The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells.

BACKGROUND

When diagnosing cancer, cellular features in biopsy samples are taken into account such as, the degree of variability of cancer cell size and shape, the proportion of actively dividing cells and invasion into neighbouring structures. Commonly used histological stains are haematoxylin (primary stain) and eosin (counterstain) which differentially label subcellular elements. Other diagnostic methods employ antibodies to particular diagnostic molecules within (via intracellular epitopes) or on the surface of cells or tissues (via extracellular epitopes) which can be made visible for microscopic analysis eg, carcino-embryonic antigen (CEA). Some specific examples are discussed below.

Prostate Cancer

The incidence of prostate cancer in the Western world is increasing at an alarming rate, having more than doubled in the past five years. It has the highest incidence of any neoplasm, is second only to lung cancer as the most common cause of cancer death in men worldwide, and is the leading cause of death in Australia [1]. Benign prostatic hyperplasia (BPH) is common in men over 50 and is a possible precursor of prostatic intraepithelial neoplasia (PIN), itself a precursor to prostate

cancer. Postmortem studies indicate that 70% of men have malignant cells in their prostate by the time they reach 80 [2]. This disease is characterised by a striking racial variation and is most prevalent in African-Americans, intermediate in Caucasians, slightly lower in Latinos, and least prevalent in Asians. In the latter group, it is nevertheless the most rapidly increasing form of neoplasm. Until recently, it was not clear if these differences were due to racial genetic variation or diet. Studies have now shown that diet is a primary influencing factor [3].

Current diagnosis and treatment of prostate cancer

Despite the gravity of this condition, diagnostic methods are few and imprecise. Current methods for assessing prognosis such as digital rectal examination (DRE), ultrasound, prostatic acid phosphatase levels, androgen ablation, prostate specific antigen (PSA) density, PSA velocity, PSA age-specific reference ranges and Gleason histopathological grading, can fail to provide reliable predictive information regarding the clinical outcome of prostate cancer [4]. For instance, studies have shown that DRE results in a 36.9% false negative rate [5]. PSA is a 33-kDa serine protease that is associated with a number of tissues besides prostate [6], is up-regulated by androgens, glucocorticoids and progestins and is thought to be involved in the regulation of growth factors. Unfortunately, serum PSA levels have an incidence of 23% false negative and 36.7% false positive diagnoses [6]. It has even been suggested that more than half of new screen-detected cases are in fact false positives [7]. Attempts to improve screening methods by the introduction of additional tests such as PSA density, velocity, and age-specific reference ranges has been equivocal. One study has shown that applying an age-specific PSA reference range that increases the upper limit of normal PSA to 4.5 ng/mL results in the failure

to detect a substantial number of clinically significant cancers [8]. Given this uncertainty, prostate biopsy is often performed to confirm malignancy but this test also has a highly unsatisfactory 23% incidence of false-negative diagnosis [9].

Treatment selection is largely dependent on clinical staging based on microscopic analysis of tissue sections [10]. This technique depends on judgment and considerable experience in relating histological appearance to clinical outcome. Unfortunately, prostate cancer tissue is notoriously heterogeneous and a vital diagnostic feature may easily be missed in the section being examined. To further complicate the situation, there have been no randomised and controlled trials to examine the outcomes of surgery and radiotherapy [2]. Treatment choices include radical prostatectomy, radiation therapy, androgen deprivation and "watchful waiting". A definitive answer to the question of "watchful waiting" versus radical intervention awaits the conclusion of the prostate cancer intervention-versus-observation trial [11]. The consequences to the patient of these decisions are serious. Radical prostatectomy for instance, often results in incontinence, impotence, bladder neck stricture and depression [12]. Clearly, improved markers that reliably differentiate between benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic cancer are urgently needed.

The role of P2X receptors in cancer

Neurotransmitters such as noradrenalin and acetylcholine act not only in the synapse and neuromuscular junction but also on transmitter-specific cell receptors in a wide variety of tissues and organs. These receptors are pore-like transmembrane channels that introduce ions into the cell. Adenosine triphosphate (ATP), best known

as the molecular currency of intracellular energy stores, was first proposed as a peripheral neurotransmitter based on its ability to contract smooth muscle [13]. ATP acts in the same manner as other neurotransmitters and can activate both the (relatively slow) G protein-coupled tissue receptors (P2Y), the more recently characterised (fast) ligand-gated purinergic ($P2X_{1-7}$) ion channels and can also act as a co-transmitter. Despite its relatively recent discovery, it is likely that the purinergic transmitter system developed very early in evolution [14].

There are currently 7 genetically distinct P2X receptor subtypes. They are as widely distributed as receptors of the cholinergic and adrenergic systems and are found in most mammalian cells [14]. These receptors constitute a new class of fast-response, membrane-bound, ligand-gated, calcium-permeable, cation-selective channels that are activated by extracellular ATP from nerve terminals or a local tissue source [15-18]. They are predominantly permeable to calcium ions but also admit other cations, such as potassium and sodium, thereby mediating depolarisation [19]. For instance, in lung epithelia, P2X channels stimulate Cl^- channel up-regulation, K^+ secretion and inhibit Na^+ absorption (21). ATP can stimulate both DNA synthesis and cell proliferation via the up-regulation of the P2X receptors [14]. This function is linked to stimulation of phospholipase C and ionic calcium release from inositol-phosphate-sensitive intracellular stores, as well as other signal transduction pathways. These actions are potentiated by the synergistic action of ATP with polypeptide growth factors [20]. The influx of calcium through the P2X receptors also triggers the secretion of other neurotransmitters, serves as a signal for the activation of calcium-dependent potassium channels, inactivates other calcium channel types,

regulates endocytotic retrieval of synaptic vesicle membranes, enhances the synthesis of neurotransmitters, regulates pools of synaptic vesicles available for secretion and triggers several forms of synaptic plasticity. The variety of responses to a single stimulation of P2X receptors suggests there are many calcium-activated pathways [21].

Extracellular ATP, acting via the purinergic receptors, also has a direct anticancer effect on human breast cancer cells, prostate carcinoma cells, human adenocarcinoma cells and fibroblast cell lines. Cytotoxic T lymphocytes and natural killer (NK) cells release ATP when they attack tumour cells [22]. Only transformed cell growth is inhibited, by inducing S phase block, apoptosis, increased permeability to nucleotides, sugar phosphates, ions and synergy with other anticancer agents. None of these effects are noted on untransformed cells [14].

Curiously, tumour cells are known to contain exceptionally high levels of ATP [23]. Adenosine and ATP both increase intratumour blood flow by stimulating nitric oxide synthesis from the endothelium, thus inducing potent vasodilation [24]. In this case ATP acts through P2Y receptors (26). Nitric oxide release is also linked to P2X receptor function. For instance, 90% of the nitric oxide synthase activity found in non-pregnant sheep myometrium is calcium ion-channel dependent [25].

Epithelial adhesive proteins also play a major role in the spread of cancer [26]. In wound healing, cell injury signals propagate via extracellular P2X receptors and intercellular gap junctions, stimulating calcium ion-induced wave propagation [27]. Intracellular calcium ions admitted by the P2X channels trigger the transport of membrane-bound organelles along microtubules, remodelling of the ECM and up-regulation of the adhesion molecule E-cadherin [28]. The myoepithelial cells found

in prostatic epithelial acinar exert important paracrine effects on carcinoma cells both *in situ* and *in vitro*. Cancer cells are also affected by high expression of ECM molecules, proteinase inhibitors and angiogenic inhibitor [29]. During metastatic invasion, extracellular calcium influx activates membrane-associated metalloproteinases that facilitate tissue penetration by invasive cells. Urokinase plasminogen activator has also been strongly implicated in the progression of several malignancies including breast and prostate cancer [30].

Current techniques for staging and diagnosing cancer need to be improved in order to provide more reliable results using relatively simple technology. It would also be advantageous to have a diagnostic method amenable to automation.

It is an object of the present invention to provide a method of identifying pre-neoplastic and/or neoplastic cells which will overcome or substantially ameliorate at least some of the deficiencies of the prior art or will provide a useful alternative.

SUMMARY OF THE INVENTION

The purinergic nervous system operates in parallel with the better known but slower acting adrenergic and cholinergic nervous systems. Like them, it operates in the brain, synapse, neuromuscular junction, peripheral nervous system and smooth muscle. The transmitter substance activating these fast-acting ligand-gated cation receptor channels is ATP, which acts by triggering purinergic receptors in tissues, resulting in a variety of metabolic responses including an influx of ions into the cell.

A unique suite of highly specific antibodies able to differentiate between the extracellular domains of each of the P2X purinergic receptor subtypes has been developed. These receptors are readily visualised using immunocytochemical methods and present in a variety of expression patterns such as cell surface, tubular

and punctate labelling. It has surprisingly been shown that the expression of P2X receptors is characteristic for pre-cancer and cancer stages and also for tissue from young vs old mammals. These changes are accompanied by marked differences in growth, extracellular matrix, metabolic and innervation factors as well as increases in subepithelial ionic calcium and microtubules. The invention therefore provides a new tool with which to diagnose pre-cancerous conditions, (such as hyperplasia), stage cancer and to investigate the basic physiology and aetiology of carcinogenesis.

According to a first aspect, the invention provides a method of staging and/or diagnosing pre-neoplastic and/or neoplastic states in a mammal, comprising detection of the P2X purinergic receptor expression profile of cells and/or tissue from said mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

According to a second aspect, the invention provides a method of determining the aetiology of carcinogenesis in a mammal, comprising detection of the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

According to a third aspect, the present invention provides a method of diagnosing prostate cancer in a subject, comprising detecting the expression profile of $P2X_1$, $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in prostate cells and/or tissue from the subject using $P2X_1$, $P2X_2$, $P2X_3$ and/or $P2X_7$ antibody respectively, wherein an increase in the intensity of the P2X purinergic receptor expression profile in the prostate cells and/or tissue, compared to the expression profile of prostate cells and/or

tissue from a prostate having benign prostate hyperplasia, is diagnostic of the presence of prostate cancer.

According to a fourth aspect, the present invention provides a method of diagnosing breast cancer in a subject comprising detecting the expression profile of $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in breast cells and/or tissue from the subject using $P2X_2$, $P2X_3$, and/or $P2X_7$ antibody respectively, wherein a decrease in the intensity of the P2X purinergic receptor expression profile in the breast cells and/or tissue compared to the expression profile of breast cells and/or tissue from the breast of a normal subject, is diagnostic of the presence of breast cancer.

According to a fifth aspect, the invention provides use of a P2X purinergic receptor antibody reagent to stage and/or diagnose a pre-neoplastic and/or neoplastic state in a mammalian subject.

According to a sixth aspect, the invention provides use of a P2X purinergic receptor antibody reagent to determine the aetiology of carcinogenesis in a mammalian subject.

According to a seventh aspect, the invention provides an isolated mammalian cell or tissue sample complexed with a P2X purinergic receptor-specific antibody reagent.

According to an eighth aspect, the invention provides a kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising means for detecting P2X purinergic receptor expression profile in a sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.

According to a ninth aspect, the invention provides an antibody reagent specific for a P2X purinergic receptor, wherein the reagent is capable of differentiating between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

According to a tenth aspect, the invention provides an antibody reagent specific for a P2X purinergic receptor when used to differentiate between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

According to an eleventh aspect, the invention provides an antibody reagent specific for P2X purinergic receptor when used to differentiate between functional and non-functional P2X receptors in cells and/or tissue.

Preferably the mammal is a human although it will be clear to the skilled addressee that the method may be applied to any mammal. Preferably the cells are prostate tissue and/or cells or breast tissue and/or cells. The cells may be obtained by biopsy but may also be obtained from a body fluid or, in the case of prostate tissue and/or cells, from digital rectal examination exudate or from semen.

Preferably the antibody reagent comprises a polyclonal antiserum. Preferably the P2X antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$ receptors, most preferably $P2X_1$, $P2X_2$, $P2X_3$ or $P2X_7$ receptors. It will be clear to those skilled in the art that the antibody reagent may be a suite of antibodies that may be polyclonal or monoclonal. It will also be clear to those skilled in the art that the suite of P2X receptor antibodies may comprise any combination of the P2X receptor subtypes, and in particular the combination of $P2X_1$, $P2X_2$, $P2X_3$ and $P2X_7$.

Preferably detection of P2X receptor expression profile is by immunohistochemical means. It will be clear to the skilled addressee that the P2X

receptors may be detected by other means including ELISA, RIA or similar immunological techniques, depending on the source of the cell or tissue sample and the reagents available. Preferably, the P2X receptors are detected by a colorimetric assay. It will also be clear to those skilled in the art that Western blotting techniques and detection of P2X purinergic receptor mRNA may be useful in determining the P2X receptor expression profile.

In the context of the present invention, the term "pre-neoplastic cells" comprises cells that are hyperplastic or hypertrophic.

In the context of the present invention the term "suite of antibodies" comprises polyclonal antibodies which contain several different antibodies specific for the same or different antigens and which are able to specifically differentiate between each of the P2X receptor subtypes. When the antibodies are monoclonal, the term "suite of antibodies" also comprises a panel of antibodies able to specifically differentiate between each of the P2X receptor subtypes.

In the context of the present invention, detection of an "expression profile" comprises detection of a pattern or intensity of expression.

Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

BRIEF DESCRIPTION OF FIGURES

Figure 1 shows an example of the level of $P2X_1$ labelling in a biopsy sample taken from a normal human prostate (left) and from a patient with advanced prostate cancer (right).

Figure 2 shows a comparison of prostate epithelium (E) from a young (12 week) rat (left), and tissue from an aged rat (18 months; right). The aged tissue shows marked hyperplasia.

Figure 3 shows an example of $P2X_1$ labelling in normal breast (right) and of the substantial down-regulation in breast tumour tissue (left).

Figures 4a, b, d and e show core biopsies from a 71-year old man with increasing PSA. Diagnosis - BPH. The H&E stain (4a) shows mild hyperplasia in the apical epithelium (arrow) of the prostatic acini (A). Figure 4d is a high-power micrograph of this area (arrow). Labelling with anti-P2X in the same area (4b) shows the complete de-expression of P2X receptors that is characteristic of BPH (4b-arrow). Figure 4e is a high-power micrograph of this area showing complete P2X de-expression in the mildly hyperplasic epithelium (4e-arrow). Figure 4c. Section of core biopsy from a 69-year old man. PSA unknown. This case was also diagnosed as BPH by H&E stain (not shown) but features distinctive Stage 1 P2X labelling, as characterised by prominent epithelial nuclei (PEN) (4c-arrow). Figure 4f is a high-power micrograph of these densely-labelled nuclei (4f-arrow), as shown in Figure 4c. Figures 4a and 4d, H&E stain. Figures 4b, c, e and f, anti-P2X immunoperoxidase label. No counterstain. Bar for low power micrographs (4a, b and c) is 1cm = 150 μm. Bar for high power micrographs (4d, e and f) is 1 cm = 40 μm.

Figures 5a-c show core biopsies (supplied as 3 cores) from a 57-year old man with increasing PSA. Two cores were diagnosed as containing areas of BPH adjacent to areas of advanced cancer, Gleason score 8. Figure 5a shows an area of BPH with no cancerous markers (5a-arrow) stained with H&E. Figure 5b is a serial section from the same block labelled with $P2X_1$ antibody. The P2X labelling is characteristic of

translocation Stage 2. The presence of these features, in tissue diagnosed by H&E staining as BPH, indicates not only the presence of preneoplastic change but that those changes are more advanced. Figure 5c is a high-power micrograph from a serial section of the acinus arrowed in Figure 5b. It depicts Stage 2 features as follows: some PEN remains (N-arrowhead) but most labelling is now punctate and cytoplasmic (P-arrow). Previous experiments have shown that each puncta is an individually-labelled P2X receptor or small localised patch of receptors. The lateral plasma membranes are clearly labelled (L-arrow) and there is labelling in the apical epithelium (A-arrow).

Figures 5d-f show a core biopsy (3 cores) from an 81-year old man with a PSA of 8.1. In this case the diagnosis was infiltrating adenocarcinoma, Gleason score 6. H&E staining (Figure 5d) showed areas of both BPH and invasive cancer (prominent nucleoli, basement membrane invasion and abnormal acinal architecture). Figure 5e shows an increase in P2X labelling in the apical epithelum (arrow) but a general decrease in overall signal. A high-power micrograph (Figure 5f) shows these P2X labelling features to be typical of P2X translocation Stage 3. The labelling is less intense than that seen in Stage 2 (Figure 5b), due to a concentration of label in the apical epithelium. The nuclei are devoid of label except for the nuclear membrane (N-arrow). The label is homogeneous rather than punctate, and is mostly found on the apical epithelium (A-arrow). At the completion of the translocation process, P2X label was commonly concentrated in the apical epithelium after which it was de-expressed (D). Figures 5a and 5d, H&E stain. Figures 5b, c, e and f, P2X immunoperoxidase label. No counterstain. Bar for low power micrographs (5a, b, d and e) is 1cm = 150 μm. Bar for high power micrographs (5c and f) is 1 cm = 40 μm.

Figures 6a-m show staining patterns in breast cancer biopsy tissue compared with normal tissue.

DESCRIPTION OF THE INVENTION

A preferred embodiment of the invention will now be described by way of example only and with reference to the accompanying Figures.

Example 1 - Immunohistochemical Procedure

The immunohistochemical method used in this study was adapted from Barclay [31]. Sections with a thickness of 8 μm were cut from unfixed, frozen tissue using a Reichert Jung 2800 Frigocut cryotome. Sections were air dried at room temperature for 1 hour, fixed for 12 hours in acetone at -20°C and air dried at room temperature for 1 hour prior to antibody labelling. They were then incubated at room temperature with one of either rabbit or sheep anti-$P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$ antibody. After washing, sections were then incubated in the secondary antibody; a 1:30 dilution of HRP-conjugated goat anti-rabbit secondary antibody (Dako) for 30 mins for rabbit primaries and HRP-conjugated goat anti-sheep secondary antibody (Dako) for sheep primaries. Slides were again rinsed and then immersed in 15% diaminobenzidine tetrahydrochloride (DAB - Sigma) for 10 minutes. Sections were rinsed, air dried and mounted in DPX (Merck). Control slides were incubated in diluent buffer during the first incubation and then treated in the same manner as the experimental slides. Negative control slides were treated in the same manner as the experimental slides except that the primary antibody was replaced with non-immune serum.

Example 2 - Antibody Production

The consensus sequences of the rat $P2X_1$ [32], $P2X_2$ [33], $P2X_3$ [34], rat $P2X_4$ [35], rat $P2X_5$ [36], rat $P2X_6$ [36], rat $P2X_7$ [37], human $P2X_7$ [38], human $P2X_1$ [39], human $P2X_3$, [40], human $P2X_4$ [41] and human $P2X_5$ [42] cloned receptors were examined for suitable epitopes following the approach adopted in Hansen et al. [15]. The non-homologous epitopes corresponding to the segment Lys199-Cys217 used in rat $P2X_1$ were utilised in rat $P2X_3$, rat $P2X_6$ and rat $P2X_7$. Variations were applied to rat $P2X_4$ which used the sequence Ile235-Gly251 to which was attached a C-terminal Cys residue for cross-linking to a 6 kDa diphtheria toxin domain. The $P2X_2$ epitope was selected from a region within the C1 domain [15], Cys130-Gly153. The rat $P2X_5$ epitope was selected from a region closer to the second transmembrane domain but still extracellular (Lys314-Ile333 to which was added a C-terminal Cys also for conjugation). Although largely homologous with rat $P2X_4$, cross-labelling of $P2X_4$ and $P2X_5$ did not occur. All antibodies against rat sequences were able to label corresponding human receptors. A separate epitope was used for the human $P2X_1$ and $P2X_7$ sequences. This was taken just C-terminal to the first transmembrane domain from Lys68-Val84 with an N-terminal Cys added for conjugation via a diphtheria toxin domain using maleimidocaproyl-N-hydroxysuccinimide. The epitope for human $P2X_3$ antibody was the equivalent sequence used for rat, while the epitopes for human $P2X_4$ and human $P2X_5$ were Cys270-Asn287 and Cys272-Ser288 respectively. All syntheses were carried out using standard t-BOC chemistry on an ABI synthesiser [43]. The peptide-antigen conjugates were suspended in water at 5 mg/mL and aliquots emulsified by mixing with Complete Freund's Adjuvant.

Emulsion volumes of 1 mL containing 2 mg of peptide were injected intramuscularly with second, third, fourth and fifth immunisations followed at 2 week intervals using Incomplete Freund's Adjuvant. Final bleeds via venepuncture were obtained at 10-12 weeks, after it was established that adequate antibody titres had been obtained in the rabbits or sheep used for each epitope. The blood was incubated at 37°C for 30 min, and stored at 4°C for 15 h after which the serum was collected following centrifugation and stored at -20°C in small aliquots. Sera were tested with an ELISA assay for antibodies specific for each peptide [15]. The antibody titre, defined as the reciprocal of the serum dilution resulting in an absorbance of 1.0 above background in the ELISA assay, was in the range 75,000±4,000 compared with 225±25 for the pre-immune samples.

Affinity purification of each of the antibodies against the specific epitope for that antibody resulted in reduced background but identical labelling trends.

Example 3 - Specificity of antibodies

Each of the P2X antisera used has been shown to possess similar distributions in many cases but with distinctly different distributions in other cases indicating that the antisera do not lack specificity. Specificity was demonstrated by affinity purification of the sera against the cognate peptides. To further verify antibody specificity, individual antibody such as the antibody to $P2X_1$ was added to cells transfected with the corresponding $P2X_1$ cDNA in the presence and absence of a 10mM concentration of the $P2X_1$ epitope. Immunolabelling and confocal imaging of the tranfected *Xenopus* oocytes demonstrated that the expressed $P2X_1$ is located, as expected, within the cell membrane and the presence of a 10mM concentration of the

cognate peptide as an absorption control resulted in the blocking of $P2X_1$ staining [18].

Individual specificity of all other antibodies has been similarly demonstrated.

Example 4 - Preparation of tissue for ultrastructural examination of morphology

Tissue was processed for morphological examination as follows: sections of approximately 3mm X 3mm in size were fixed in 2.5% glutaraldehyde in 0.1M Tris buffer pH 7.2 for 1 hour. They were then washed and post fixed in 2% aqueous osmium tetroxide for 2 hours. After further washing, the tissue was dehydrated in a graded series of alcohols and embedded in Spurr's resin. Curing was carried out at 50^0C for 18 hours. 100nm sections were then cut with a diamond knife, stained with uranyl acetate and Reynolds lead citrate in the usual manner and examined in a Phillips 400 transmission electron microscope.

Example 5 - Ultrastructural Immunocytochemistry

The method of Slater [44] was used. In short, thin sections (100nm) were cut and retrieved on 300 mesh nickel grids. After incubation in blocking solution (1% BSA in PBS) for 30 min, the sections were placed on the surface of a drop of the blocking solution (with the addition of 0.05% Tween 20) containing HRP-conjugated goat anti-rabbit secondary antibody or HRP-conjugated goat anti-sheep secondary antibody (diluted 1:100) for 1 h at room temperature. Grids were then rinsed three times for 10 min in PBS and placed on drops of goat anti-rabbit secondary antibody conjugated to 10 nm gold (Nanoprobe) for 1 h at room temperature. The grids were then washed twice with PBS followed by one wash with distilled water, for 10 min each and then placed in the vapour of 2% aqueous osmium tetroxide for 1 minute. Sections were then stained with aqueous uranyl acetate solution for 20 min, lead

citrate for 10 min, rinsed twice for 10 min in distilled water and examined with a Phillips 400 electron microscope at 80 kV.

Example 6 – P2X receptors in human cancer tissue

In a study of 4 normal and 6 human prostate cancer cases, $P2X_1$, $P2X_3$, and $P2X_4$ subtypes were markedly increased in human prostate cancer tissue. There was no labelling at all for these subtypes in normal tissue. The labelling patterns for $P2X_1$ (Figure 1) in the cancerous tissue were particularly interesting in that there was a greater proportion of labelled acinar epithelial cells with each stage of prostate disease, suggesting a direct correlation between neoplastic transformation and the extent of $P2X_1$ acinar labelling. $P2X_5$ was also increased in some prostate cancer cells (results not shown). There was very little or no labelling for $P2X_5$ in normal tissue.

Example 7 – P2X receptors, growth, innervation, and metabolic factors, ionic calcium modulation in young vs aged Wistar rats

P2X receptors and apoptosis:

Studies comparing prostates from four 12 week-old rats and four 1.5 year-old rats resulted in the detection of a marked increase in epithelial hyperplasia in the aged rats, resembling BPH in humans (Figure 2). As with the human cancer tissue, $P2X_1$, $P2X_3$, and $P2X_4$ receptors and tyrosine kinase A receptor antibody were up-regulated in the prostatic epithelium of aged rats, when compared with that of young rats. As previously discussed, this indicates an increase in protein phosphorylation (activation), DNA synthesis, intracellular microtubule expression (organelle transport), up-regulation of adjacent receptors for other neurotransmitters, cell proliferation and an influx of ions (primarily ionic calcium) into the epithelial cells

indicating apoptosis. An increase in alpha (1B) (voltage-gated calcium channel), and a reduction in the calcium-regulating hormone stanniocalcin was also observed in the aged rat prostates. PDGF and IGF-1 both inhibit apoptosis and were decreased in the aged rats [45]. Thus, the aged rat prostate undergoes apoptosis and similar changes in P2X receptor expression as human prostate cancer tissue, and therefore may be used to investigate prostate cancer aetiology.

Innervation, other receptors and metabolic factors:

In the aged rats, there was an increase in microtubular structures in the fibromuscular septa subjacent to the prostatic epithelium. These structures appeared similar in micrographs depicting the apoptosis-associated purinergic receptors $P2X_1$, $P2X_7$, ionic calcium, and the innervation factors VAMP, muscarinic receptor (M2), SV-2, SNAP-25, S100, and transferrin receptor, all of which were up-regulated in the aged rats. Alpha (1B) voltage-gated calcium channels and tyrosine kinase A receptors were also up-regulated in the aged rats. Stanniocalcin was down-regulated while the $P2X_1$ and $P2X_7$ apoptotic calcium channel receptors were up-regulated. These data indicate an increase of calcium ion inflow, metabolic rate, microtubule transport and innervation of the prostatic epithelium in the aged rats, and also suggest that this model could be used to investigate human prostate cancer.

Example 8 - Breast cancer cell lines

In 6 breast cancer cell lines supplied as frozen sections, $P2X_1$, $P2X_3$, and $P2X_4$ purinergic subtypes were labelled using the same techniques employed in the labelling of prostate tissues. The labelling pattern (Figure 3) was suggestive of the labelling patterns seen in both human prostate cancer tissue (Figure 1) and the prostate of the male aged Wistar rat (Figure 2).

Example 9 - Prostate cancer diagnoses (Figures 4a-f and 5a-f)

The expression characteristics of the purinergic receptor calcium channels ($P2X_{1-7}$) were examined in normal and pathological prostate tissue from 65 cases representing each stage of prostate disease: normal, BPH, preneoplastic and cancerous (Gleason's grade 5-9). Clear translocation features were noted in tissue labelled with $P2X_1$, $P2X_2$, $P2X_3$ and $P2X_7$. After a lengthy process of optimisation and standardisation of P2X antibody production and labelling protocols, a standardised protocol was developed. A mixture of $P2X_1$, $P2X_2$, $P2X_3$ and $PX2_7$ subtypes at a concentration of 0.5 μg / mL IgG each, diluted 1:100 with PBS, proved to be the best reagent for demonstrating the translocation features described. $P2X_4$, $P2X_5$ or $P2X_6$ labelling was of lesser significance. Using this reagent to label tissue sections from each category of prostate cancer it was found that there was a sequential expression and translocation of P2X labelling from the nuclei to the cytoplasm and lateral plasma membranes, ultimately expressing primarily in the apical epithelium, as cancer progressed (Figs 4f, 5c, 5f).

P2X labelling was completely de-expressed in BPH tissue (Figs 4b, 4e). Preneoplastic P2X translocation occurred in three distinct stages. Stage 1 was characterised by dense, prominent P2X-labelled epithelial nuclei (PEN) on a pale background (Figs 4c, 4f). Stage 2 featured a progressive de-expression of PEN and the appearance of dense and markedly punctate cytoplasmic labelling, nuclear membrane and lateral plasma membrane labelling, and an increasing signal on the apical epithelium (Figs 5b, 5c). Stage 3 was represented by nuclei labelled only on the nuclear membrane (NO), no cytoplasmic signal, homogeneous rather than punctate labelling, and a dense label in the apical epithelium (Figs 5e, 5f).

In the present study, 56% of cases diagnosed as normal or BPH by haematoxylin and eosin (H&E) staining, showed Stage 1 or Stage 2 P2X labelling. The remaining cases, ranging from Gleason score G5 to G9, had P2X Stage 2 or 3 labelling features. Stage 3 labelling was always accompanied by the histological features of cancer (Fig 5e). True non-neoplastic BPH tissue was easily distinguished by the complete de-expression of all P2X subtypes in the epithelium and stroma. We propose that biopsy tissue that has been histologically diagnosed as normal but displays P2X labelling features, may be in the process of early (preneoplastic) transformation at a metabolic level. The demonstration of Stage 2 features in 'normal' tissue suggests that the preneoplastic process is more advanced in that tissue. The P2X labelling features described are stage-specific and uniform throughout the entire area of cells representative of each histological classification. In cores that contained both BPH and cancer areas, P2X labelling was clearly and uniformly demarcated into either BPH or one of the cancer labelling patterns. It is proposed that this technique can be used to exclude (and reassure) patients with non-neoplastic prostatic conditions from those with early cancer and also identify rapidly-developing preneoplasia, that may lead to malignancy. This information may permit earlier and more accurate treatment decisions.

Example 10 - Breast cancer diagnoses

Subtypes $P2X_2$, $P2X_3$, and $P2X_7$ are significantly down-regulated in breast cancer biopsy tissue compared with normal. Subtypes $P2X_1$, $P2X_4$, $P2X_5$ and $P2X_6$ were unlabeled in both the normal and cancerous tissue. Tissue was pre-incubated with 3% hydrogen peroxide and 5% horse serum to suppress endogenous peroxidase activity. Examples of the staining patterns are shown in Figs 6a-m.

Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.

References

1. Lian FR, Bhuiyan M, Li YW, Wall N, Kraut M, and Sarkar FH, 1998 Genistein-Induced G(2)-M Arrest, P21(Waf1) Upregulation, and Apoptosis in a Non-Small-Cell Lung Cancer Cell Line. Nutr. & Cancer. 31:184-191.

2. Hoey J, 1998 Prostate cancer: progress and perplexity. CMAJ 159:1-3.

3. Kolonel LN, Nomura AM, Hinds MW, Hirohata T, Hankin JH, and Lee J, 1983 Role of diet in cancer incidence in Hawaii. Cancer Res. 43:2397s-2402s.

4. Festuccia C, Vincentini C, di Pasquale AB, Aceto G, Zazzeroni F, Miano L, and Bologna M, 1995 Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol. Res. 7:131-138.

5. Saxena S, Mohanty NK, and Jain AK, 1997 Screening of prostate cancer in males with prostatism. Ind. J. Pathol. Micro. 40:441-450.

6. Diamandis EP and Yu H, 1997 Nonprostatic sources of prostate-specific antigen. Urol. Clin. Nth. Am. 24:275-282.

7. Weyler J, 1999 Prostate cancer: screening or watchful waiting? Ann. Oncol. 9:9-11.

8. Bassler TJ, Orozco R, Bassler IC, Odowd GJ, and Stamey TA, 1998 Most Prostate Cancers Missed By Raising the Upper Limit of Normal Prostate-Specific Antigen For Men in Their Sixties Are Clinically Significant. Urol. 52:1064-1069.

9. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, and Fair WR, 1998 Incidence and clinical significance of false-negative sextant prostate biopsies. J. Urol. 159:1247-1250.

10. Gao X, Porter AT, Grignon DJ, Pontes JE, and Honn KV, 1997 Diagnostic and prognostic markers for human prostate cancer. Prostate 31:264-281.

11. Small EJ, 1997 Prostate cancer. Curr. Opin. Oncol. 9:277-286.

12. Moul JW, Mooneyhan RM, Kao TC, McLeod DG, and Cruess DF, 1998 Preoperative and Operative Factors to Predict Incontinence, Impotence and Stricture After Radical Prostatectomy. Prost. Can. & Prost. Dis. 1:242-249.

13. Drury A and Szent-Gyorgyi A, 1929 The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. 68:213-237.

14. Abbracchio M and Burnstock G, 1998 Purinergic signalling: pathophysiological roles. Jap. J. Pharmacol. 78:113-145.

15. Hansen MA, Barden JA, Balcar VJ, Keay KA, and Bennett MR, 1997 Structural motif and characteristics of the extracellular domain of P2X receptors. Biochem. Biophys. Res. Comm. 236:670-675.

16. Hansen MA, Balcar VJ, Barden JA, and Bennett MR, 1998 The distribution of single P2X1-receptor clusters on smooth muscle in relation to nerve varicosities in the rat urinary bladder. J. Neurocytol. 27:529-539.

17. Hansen M, Dutton J, Balcar V, Barden J, and Bennett M, 1999 P2x (purinergic) receptor distributions in rat blood vessels. J. Auton. Nerv. Syst. 75:147-155.

18. Dutton J, Hansen M, Balcar V, Barden J, and Bennett MR, 1998 Development of P2X receptor clusters on smooth muscle cells in relation to nerve varicosities in the rat urinary bladder. J. Neurocytol. in press.

19. Filipovic DM, Adebanjo OA, Zaidi M, and Reeves WB, 1998 Functional and molecular evidence for P2x receptors in Llc-Pk1 Cells. Am. J. Physiol. 43:F1070-F1077.

20. Abbracchio M, 1996 P1 and P2 receptors in cell growth and differentiation. Drug. Dev. Res. 39:393-406.

21. Augustine G, Betz H, Bommert K, Charlton M, DeBello W, Hans M, and Swandulla D, Molecular pathways for presynaptic calcium signalling, in Molecular and Cellular Mechanisms of Neurotransmitter Release, L. Stjarne, *et al.*, Editors. 1994, Raven Press: New York. p. 139-155.

22. Di Firgilio F, Pizzo P, Zanovello P, Bronte V, and Collavo D, 1990 Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Immunol. Today 11:274-277.

23. Siems W, Grune T, Schmidt H, Tikhonov Y, and Pimenov A, 1993 Purine nucleotide levels in host tissues of Ehrlich ascities tumor-bearing mice in different growth phases of the tumor. Cancer Res. 53:5143-5147.

24. Natori Y, Moriguchi M, Fujiwara S, Takeshita I, Fukui M, Iwaki T, and Kanaide H, 1992 Effects of L-NMMA and L-NNA on the selective ATP-induced enhancement of intratumoral blood flow. J. Cereb. Blood Flow Metab. 12:120-127.

25. Figueroa JP and Massmann GA, 1995 Estrogen increases nitric oxide synthase activity in the uterus of nonpregnant sheep. Am. J. Obstet. Gynecol. 173:1539-1545.

26. Rabbani SA and Xing RH, 1998 Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. 12:911-920.

27. Ciccarelli R, Di Iorio P, Ballerini P, Ambrosini G, Giuliani P, Tibone G, and Caciagli F, 1994 Effects of exogenous ATP and related analogues on the proliferation rate of dissociated primary cultures of rat astrocytes. J. Neurosci. Res. 39:556-566.

28. Potter SW, Gaza G, and Morris JE, 1996 Estradiol induces E-cadherin degradation in mouse uterine epithelium during the estrous cycle and early pregnancy. J. Cell. Physiol. 169:1-14.

29. Kedeshian P, Sternlicht MD, Nguyen M, Shao ZM, and Barsky SH, 1998 Humatrix, a Novel Myoepithelial Matrical Gel With Unique Biochemical and Biological Properties. Cancer Lett. 123:215-226.

30. Dethlefsen SM, Raab G, Moses MA, Adam RM, Klagsbrun M, and Freeman MR, 1998 Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J. Cell. Biochem. 69:143-153.

31. Barclay A, 1981 The localisation of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues. Immunology 42:593-600.

32. Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, and Buell G, 1994 A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP [see comments]. Nature 371:516-519.

33. Brake AJ, Wagenbach MJ, and Julius D, 1994 New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 371:519-523.

34. Lewis C, Neidhart S, Holy C, North RA, Buell G, and Surprenant A, 1995 Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons [see comments]. Nature 377:432-435.

35. Buell G, Collo G, and Rassendren F, 1996 P2X receptors: an emerging channel family. Eur. J. Neurosci. 8:2221-2228.

36. Collo G, North RA, Kawashima E, Merlo-Pich E, Neidhart S, Surprenant A, and Buell G, 1996 Cloning OF P2X5 and P2X6 receptors and the distribution and

properties of an extended family of ATP-gated ion channels. J. Neurosci. 16:2495-2507.

37. Surprenant A, Rassendren F, Kawashima E, North RA, and Buell GS, 735-738., 1996 The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272:735-738.

38. Rassendren F, Buell GN, Virginio C, Collo G, North RA, and Surprenant A, 1997 The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J. Biol. Chem. 272:5482-5486.

39. Longhurst PA, Schwegel T, Folander K, and Swanson R, 1996 The human P2x1 receptor: molecular cloning, tissue distribution, and localization to chromosome 17. Biochim. Biophys. Acta 1308:185-188.

40. Garcia-Guzman M, Stuhmer W and Soto F, 1997 Molecular characterization and pharmacological properties of the human P2X3 purinoceptor Brain Res. Mol. Brain Res. 47, 59-66.

41. Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund PE, and Stuhmer W, 1997 Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol. Pharmacol. 51, 109-118.

42. Le KT, Paquet M, Nouel D, Babinski K and Seguela P, 1997 Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system FEBS Lett. 418, 195-199.

43. Barden JA, Cuthbertson RM, Jia-Zhen W, Moseley JM, and Kemp BE, 1997 Solution structure of parathyroid hormone related protein (residues 1-34) containing an Ala substituted for an Ile in position 15 (PTHrP[Ala15]-(1-34)). J. Biol. Chem. 272:29572-29578.

44. Slater M, Patava J, Kingham K, and Mason RS, 1994 Modulation of growth factor incorporation into the extracellular matrix of human osteoblast-like cells in vitro by 17β estradiol. Am. J. Physiol. 267:E990-E1001.

45. Kiess W and Gallaher B, 1998 Hormonal control of programmed cell death/apoptosis. Eur. J. Endocrinol. 138:482-491.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method of staging and/or diagnosing pre-neoplastic and/or neoplastic states in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from said mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

2. A method of determining the aetiology of carcinogenesis in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

3. A method according to claim 1 or claim 2 wherein the mammal is a human.

4. A method according to any one of claims 1 to 3 wherein the cells are prostate tissue cells.

5. A method according to any one of claims 1 to 3 wherein the cells are breast tissue cells.

6. A method according to any one of claims 1 to 5 wherein the cells are obtained by biopsy.

7. A method according to any one of claims 1 to 4 wherein the cells are obtained from digital rectal examination exudate and/or semen.

8. A method according to any one of claims 1 to 3 wherein the cells are obtained from a body fluid.

9. A method according to any one of claims 1 to 8 wherein detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent.

10. A method according to claim 9 wherein the P2X antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

11. A method according to claim 10 wherein the antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$ or $P2X_7$.

12. A method of diagnosing prostate cancer in a subject, comprising detecting the expression profile of $P2X_1$, $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in prostate cells and/or tissue from the subject using $P2X_1$, $P2X_2$, $P2X_3$ and/or $P2X_7$ antibody respectively, wherein an increase in the intensity of the P2X purinergic receptor expression profile in the prostate cells and/or tissue, compared to the expression profile of prostate cells and/or tissue from a prostate having benign prostate hyperplasia, is diagnostic of the presence of prostate cancer.

13. A method of diagnosing breast cancer in a subject comprising detecting the expression profile of $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in breast cells and/or tissue from the subject using $P2X_2$, $P2X_3$, and/or $P2X_7$ antibody respectively, wherein a decrease in the intensity of the P2X purinergic receptor expression profile in the breast cells and/or tissue compared to the expression profile of breast cells and/or tissue from the breast of a normal subject, is diagnostic of the presence of breast cancer.

14. A method according to any one of claims 9 to 13 wherein the antibody reagent comprises a polyclonal antiserum.

15. A method according to any one of claims 9 to 13 wherein the antibody reagent comprises a monoclonal antiserum.

16. A method according to any one of claims 9 to 14, wherein the antibody reagent is a suite of polyclonal antibodies.

17. A method according to any one of claims 9 to 13 or 15, wherein the antibody reagent is a suite of monoclonal antibodies.

18. A method according to claim 16 or claim 17 wherein the suite of P2X receptor antibodies comprises a combination of the P2X receptor sub-types antibodies.

19. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by immunohistochemical means.

20. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by ELISA.

21. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by RIA.

22. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by Western blot.

23. A method according to any one of claims 1 to 18 wherein detection of the P2X purinergic receptor expression is by detection of P2X purinergic receptor mRNA.

24. Use of a P2X purinergic receptor antibody reagent to stage and/or diagnose a pre-neoplastic and/or neoplastic state in a mammalian subject.

25. Use of a P2X purinergic receptor antibody reagent to determine the aetiology of carcinogenesis in a mammalian subject.

26. Use according to claim 24 or claim 25 wherein the mammal is a human.

27. Use according to any one of claims 24 to 26 wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.

28. Use according to any one of claims 24 to 26 wherein the P2X purinergic receptor antibody is a monoclonal antiserum.

29. Use according to claim 27 or claim 28 wherein the P2X purinergic receptor antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

30. Use according to claim 29 wherein the P2X purinergic receptor antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$ or $P2X_7$.

31. Use according to any one of claims 26 to 27 or 29 and 30, wherein the P2X purinergic receptor antibody reagent is a suite of polyclonal antibodies.

32. Use according to any one of claims 24 to 26 or 28 to 30, wherein the P2X purinergic receptor antibody reagent is a suite of monoclonal antibodies.

33. Use according to claim 31 or claim 32 wherein the suite of P2X receptor antibodies comprises a combination of antibodies specific for $P2X_1$, $P2X_2$, $P2X_3$ and $P2X_7$.

34. An isolated mammalian cell or tissue sample complexed with a P2X purinergic receptor-specific antibody reagent.

35. An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor-specific antibody reagent comprises polyclonal antiserum.

36. An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor antibody reagent comprises monoclonal antiserum.

37. An isolated mammalian cell or tissue sample according to claim 35 or claim 36 wherein the P2X purinergic receptor-specific antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

38. An isolated mammalian cell or tissue sample according to claim 37 wherein the P2X purinergic receptor-specific antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, or $P2X_7$.

39. A kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising means for detection of P2X purinergic receptor expression profile in a

sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.

40. A kit according to claim 39 wherein the detection means comprises an antibody reagent specific for a P2X purinergic receptor.

41. A kit according to claim 40 wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.

42. A kit according to claim 40 wherein the P2X purinergic receptor antibody reagent comprises a monoclonal antiserum.

43. A kit according to claim 42 wherein the P2X purinergic receptor antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

44. A kit according to claim 43 wherein the antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, or $P2X_7$.

45. A kit according to any one of claims 39 to 44 wherein the P2X purinergic receptor expression profile is detected by a colorimetric assay.

46. A kit according to claim 45 wherein the assay is an ELISA.

47. A kit according to claim 45 wherein the assay is an RIA.

48. A kit according to any one of claims 39 to 47 wherein the sample is a body fluid.

49. A kit according to any one of claims 39 to 47 wherein the sample is a digital rectal examination exudate.

50. A kit according to any one of claims 39 to 48 wherein the sample is a biopsy sample.

51. An antibody reagent specific for a P2X purinergic receptor, wherein the reagent is capable of differentiating between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

52. An antibody reagent specific for a P2X purinergic receptor when used to differentiate between functional and non-functional P2X receptors in cells and/or tissue.

53. An antibody reagent according to claim 51 or claim 52 wherein the antibody reagent comprises a polyclonal antiserum.

54. An antibody reagent according to claim 51 or claim 52 wherein the antibody reagent comprises a monoclonal antiserum.

55. An antibody reagent according to any one of claims 51 to 54 wherein the P2X antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

56. An antibody reagent according to claim 55 wherein the antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, or $P2X_7$.

ABSTRACT

The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells.

Fig 1

The following figure shows an example of the level of P2X1 labeling in a biopsy sample taken from a normal human prostate (left) and from a patient with advanced prostate cancer (right).

Normal Prostate **Prostate Cancer**

PCT/AU00/00363
Received 4 August 2000

Fig 2

The following Figure shows that, compared with prostate epithelium (E) from a young (12 week) rat (left), tissue from an aged rat (18 months) shows marked hyperplasia (right).

Fig 3

The following figure shows an example of P2X1 labeling in normal breast (right) and a substantial down-regulation in breast tumour tissue (left).



Fig 4



Fig 5

Fig 6

(a) Low Power: normal tissue, P2X2 label.

Bars - 50µm.



(b) Low Power: breast cancer, P2x2.



(c) Low Power: normal tissue, H&E stain.

Bars = 50µm.

(d) Low Power: breast cancer, H&E stain.

Fig 6



(e) High Power: normal tissue, H&E stain.

(f) High Power: breast cancer, H&E stain.

(g) High Power: normal tissue, P2x2 label.

(h) High Power: cancer tissue, P2x2 label.

Fig 6



(i) High Power: normal tissue, P2x3 label.

(j) High Power: cancer tissue, P2x3 label.

Bars 20 µm. Arrow = epithelial acinus.

(k) High Power: normal tissue, P2x7 label.

(l) High Power: cancer tissue, P2x7 label.

Bars = 20µm. Arrows = epithelial acinus.

Fig 6

(m) Control: normal tissue, bar = 50 µm, erythrocytes with residual endogenase activity (arrow)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/06259 A1

(51) International Patent Classification[7]: G01N 33/574

(21) International Application Number: PCT/AU00/00363

(22) International Filing Date: 26 April 2000 (26.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PP 9911 21 April 1999 (21.04.1999) AU

(71) Applicant *(for all designated States except US)*: **THE UNIVERSITY OF SYDNEY** [AU/AU]; Business Liaison Office, John Woolley Building A20, Cnr Manning Road & Western Avenue, Sydney, NSW 2006 (AU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **SLATER, Michael** [AU/AU]; Flat 3/511 Burwood Road, Belmore, NSW 2192 (AU). **BARDEN, Julian** [AU/AU]; 48 Mawarra Crescent, Marsfield, NSW 2122 (AU).

(74) Agent: **BALDWIN SHELSTON WATERS**; 60 Margaret Street, Sydney, NSW 2000 (AU).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/06259 A1

(54) Title: A METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS

(57) Abstract: The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells.

A METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS

TECHNICAL FIELD

The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells.

BACKGROUND

When diagnosing cancer, cellular features in biopsy samples are taken into account such as, the degree of variability of cancer cell size and shape, the proportion of actively dividing cells and invasion into neighbouring structures. Commonly used histological stains are haematoxylin (primary stain) and eosin (counterstain) which differentially label subcellular elements. Other diagnostic methods employ antibodies to particular diagnostic molecules within (via intracellular epitopes) or on the surface of cells or tissues (via extracellular epitopes) which can be made visible for microscopic analysis eg, carcino-embryonic antigen (CEA). Some specific examples are discussed below.

Prostate Cancer

The incidence of prostate cancer in the Western world is increasing at an alarming rate, having more than doubled in the past five years. It has the highest incidence of any neoplasm, is second only to lung cancer as the most common cause of cancer death in men worldwide, and is the leading cause of death in Australia [1]. Benign prostatic hyperplasia (BPH) is common in men over 50 and is a possible precursor of prostatic intraepithelial neoplasia (PIN), itself a precursor to prostate

cancer. Postmortem studies indicate that 70% of men have malignant cells in their prostate by the time they reach 80 [2]. This disease is characterised by a striking racial variation and is most prevalent in African-Americans, intermediate in Caucasians, slightly lower in Latinos, and least prevalent in Asians. In the latter group, it is nevertheless the most rapidly increasing form of neoplasm. Until recently, it was not clear if these differences were due to racial genetic variation or diet. Studies have now shown that diet is a primary influencing factor [3].

Current diagnosis and treatment of prostate cancer

Despite the gravity of this condition, diagnostic methods are few and imprecise. Current methods for assessing prognosis such as digital rectal examination (DRE), ultrasound, prostatic acid phosphatase levels, androgen ablation, prostate specific antigen (PSA) density, PSA velocity, PSA age-specific reference ranges and Gleason histopathological grading, can fail to provide reliable predictive information regarding the clinical outcome of prostate cancer [4]. For instance, studies have shown that DRE results in a 36.9% false negative rate [5]. PSA is a 33-kDa serine protease that is associated with a number of tissues besides prostate [6], is up-regulated by androgens, glucocorticoids and progestins and is thought to be involved in the regulation of growth factors. Unfortunately, serum PSA levels have an incidence of 23% false negative and 36.7% false positive diagnoses [6]. It has even been suggested that more than half of new screen-detected cases are in fact false positives [7]. Attempts to improve screening methods by the introduction of additional tests such as PSA density, velocity, and age-specific reference ranges has been equivocal. One study has shown that applying an age-specific PSA reference range that increases the upper limit of normal PSA to 4.5 ng/mL results in the failure

to detect a substantial number of clinically significant cancers [8]. Given this uncertainty, prostate biopsy is often performed to confirm malignancy but this test also has a highly unsatisfactory 23% incidence of false-negative diagnosis [9].

Treatment selection is largely dependent on clinical staging based on microscopic analysis of tissue sections [10]. This technique depends on judgment and considerable experience in relating histological appearance to clinical outcome. Unfortunately, prostate cancer tissue is notoriously heterogeneous and a vital diagnostic feature may easily be missed in the section being examined. To further complicate the situation, there have been no randomised and controlled trials to examine the outcomes of surgery and radiotherapy [2]. Treatment choices include radical prostatectomy, radiation therapy, androgen deprivation and "watchful waiting". A definitive answer to the question of "watchful waiting" versus radical intervention awaits the conclusion of the prostate cancer intervention-versus-observation trial [11]. The consequences to the patient of these decisions are serious. Radical prostatectomy for instance, often results in incontinence, impotence, bladder neck stricture and depression [12]. Clearly, improved markers that reliably differentiate between benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic cancer are urgently needed.

The role of P2X receptors in cancer

Neurotransmitters such as noradrenalin and acetylcholine act not only in the synapse and neuromuscular junction but also on transmitter-specific cell receptors in a wide variety of tissues and organs. These receptors are pore-like transmembrane channels that introduce ions into the cell. Adenosine triphosphate (ATP), best known

as the molecular currency of intracellular energy stores, was first proposed as a peripheral neurotransmitter based on its ability to contract smooth muscle [13]. ATP acts in the same manner as other neurotransmitters and can activate both the (relatively slow) G protein-coupled tissue receptors (P2Y), the more recently characterised (fast) ligand-gated purinergic ($P2X_{1-7}$) ion channels and can also act as a co-transmitter. Despite its relatively recent discovery, it is likely that the purinergic transmitter system developed very early in evolution [14].

There are currently 7 genetically distinct P2X receptor subtypes. They are as widely distributed as receptors of the cholinergic and adrenergic systems and are found in most mammalian cells [14]. These receptors constitute a new class of fast-response, membrane-bound, ligand-gated, calcium-permeable, cation-selective channels that are activated by extracellular ATP from nerve terminals or a local tissue source [15-18]. They are predominantly permeable to calcium ions but also admit other cations, such as potassium and sodium, thereby mediating depolarisation [19]. For instance, in lung epithelia, P2X channels stimulate Cl^- channel up-regulation, K^+ secretion and inhibit Na^+ absorption (21). ATP can stimulate both DNA synthesis and cell proliferation via the up-regulation of the P2X receptors [14]. This function is linked to stimulation of phospholipase C and ionic calcium release from inositol-phosphate-sensitive intracellular stores, as well as other signal transduction pathways. These actions are potentiated by the synergistic action of ATP with polypeptide growth factors [20]. The influx of calcium through the P2X receptors also triggers the secretion of other neurotransmitters, serves as a signal for the activation of calcium-dependent potassium channels, inactivates other calcium channel types,

regulates endocytotic retrieval of synaptic vesicle membranes, enhances the synthesis of neurotransmitters, regulates pools of synaptic vesicles available for secretion and triggers several forms of synaptic plasticity. The variety of responses to a single stimulation of P2X receptors suggests there are many calcium-activated pathways [21].

Extracellular ATP, acting via the purinergic receptors, also has a direct anticancer effect on human breast cancer cells, prostate carcinoma cells, human adenocarcinoma cells and fibroblast cell lines. Cytotoxic T lymphocytes and natural killer (NK) cells release ATP when they attack tumour cells [22]. Only transformed cell growth is inhibited, by inducing S phase block, apoptosis, increased permeability to nucleotides, sugar phosphates, ions and synergy with other anticancer agents. None of these effects are noted on untransformed cells [14].

Curiously, tumour cells are known to contain exceptionally high levels of ATP [23]. Adenosine and ATP both increase intratumour blood flow by stimulating nitric oxide synthesis from the endothelium, thus inducing potent vasodilation [24]. In this case ATP acts through P2Y receptors (26). Nitric oxide release is also linked to P2X receptor function. For instance, 90% of the nitric oxide synthase activity found in non-pregnant sheep myometrium is calcium ion-channel dependent [25].

Epithelial adhesive proteins also play a major role in the spread of cancer [26]. In wound healing, cell injury signals propagate via extracellular P2X receptors and intercellular gap junctions, stimulating calcium ion-induced wave propagation [27]. Intracellular calcium ions admitted by the P2X channels trigger the transport of membrane-bound organelles along microtubules, remodelling of the ECM and up-regulation of the adhesion molecule E-cadherin [28]. The myoepithelial cells found

in prostatic epithelial acinar exert important paracrine effects on carcinoma cells both *in situ* and *in vitro*. Cancer cells are also affected by high expression of ECM molecules, proteinase inhibitors and angiogenic inhibitor [29]. During metastatic invasion, extracellular calcium influx activates membrane-associated metalloproteinases that facilitate tissue penetration by invasive cells. Urokinase plasminogen activator has also been strongly implicated in the progression of several malignancies including breast and prostate cancer [30].

Current techniques for staging and diagnosing cancer need to be improved in order to provide more reliable results using relatively simple technology. It would also be advantageous to have a diagnostic method amenable to automation.

It is an object of the present invention to provide a method of identifying pre-neoplastic and/or neoplastic cells which will overcome or substantially ameliorate at least some of the deficiencies of the prior art or will provide a useful alternative.

SUMMARY OF THE INVENTION

The purinergic nervous system operates in parallel with the better known but slower acting adrenergic and cholinergic nervous systems. Like them, it operates in the brain, synapse, neuromuscular junction, peripheral nervous system and smooth muscle. The transmitter substance activating these fast-acting ligand-gated cation receptor channels is ATP, which acts by triggering purinergic receptors in tissues, resulting in a variety of metabolic responses including an influx of ions into the cell.

A unique suite of highly specific antibodies able to differentiate between the extracellular domains of each of the P2X purinergic receptor subtypes has been developed. These receptors are readily visualised using immunocytochemical methods and present in a variety of expression patterns such as cell surface, tubular

and punctate labelling. It has surprisingly been shown that the expression of P2X receptors is characteristic for pre-cancer and cancer stages and also for tissue from young vs old mammals. These changes are accompanied by marked differences in growth, extracellular matrix, metabolic and innervation factors as well as increases in subepithelial ionic calcium and microtubules. The invention therefore provides a new tool with which to diagnose pre-cancerous conditions, (such as hyperplasia), stage cancer and to investigate the basic physiology and aetiology of carcinogenesis.

According to a first aspect, the invention provides a method of staging and/or diagnosing pre-neoplastic and/or neoplastic states in a mammal, comprising detection of the P2X purinergic receptor expression profile of cells and/or tissue from said mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

According to a second aspect, the invention provides a method of determining the aetiology of carcinogenesis in a mammal, comprising detection of the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

According to a third aspect, the present invention provides a method of diagnosing prostate cancer in a subject, comprising detecting the expression profile of $P2X_1$, $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in prostate cells and/or tissue from the subject using $P2X_1$, $P2X_2$, $P2X_3$ and/or $P2X_7$ antibody respectively, wherein an increase in the intensity of the P2X purinergic receptor expression profile in the prostate cells and/or tissue, compared to the expression profile of prostate cells and/or

tissue from a prostate having benign prostate hyperplasia, is diagnostic of the presence of prostate cancer.

According to a fourth aspect, the present invention provides a method of diagnosing breast cancer in a subject comprising detecting the expression profile of $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in breast cells and/or tissue from the subject using $P2X_2$, $P2X_3$, and/or $P2X_7$ antibody respectively, wherein a decrease in the intensity of the P2X purinergic receptor expression profile in the breast cells and/or tissue compared to the expression profile of breast cells and/or tissue from the breast of a normal subject, is diagnostic of the presence of breast cancer.

According to a fifth aspect, the invention provides use of a P2X purinergic receptor antibody reagent to stage and/or diagnose a pre-neoplastic and/or neoplastic state in a mammalian subject.

According to a sixth aspect, the invention provides use of a P2X purinergic receptor antibody reagent to determine the aetiology of carcinogenesis in a mammalian subject.

According to a seventh aspect, the invention provides an isolated mammalian cell or tissue sample complexed with a P2X purinergic receptor-specific antibody reagent.

According to an eighth aspect, the invention provides a kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising means for detecting P2X purinergic receptor expression profile in a sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.

According to a ninth aspect, the invention provides an antibody reagent specific for a P2X purinergic receptor, wherein the reagent is capable of differentiating between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

According to a tenth aspect, the invention provides an antibody reagent specific for a P2X purinergic receptor when used to differentiate between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

According to an eleventh aspect, the invention provides an antibody reagent specific for P2X purinergic receptor when used to differentiate between functional and non-functional P2X receptors in cells and/or tissue.

Preferably the mammal is a human although it will be clear to the skilled addressee that the method may be applied to any mammal. Preferably the cells are prostate tissue and/or cells or breast tissue and/or cells. The cells may be obtained by biopsy but may also be obtained from a body fluid or, in the case of prostate tissue and/or cells, from digital rectal examination exudate or from semen.

Preferably the antibody reagent comprises a polyclonal antiserum. Preferably the P2X antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$ receptors, most preferably $P2X_1$, $P2X_2$, $P2X_3$ or $P2X_7$ receptors. It will be clear to those skilled in the art that the antibody reagent may be a suite of antibodies that may be polyclonal or monoclonal. It will also be clear to those skilled in the art that the suite of P2X receptor antibodies may comprise any combination of the P2X receptor subtypes, and in particular the combination of $P2X_1$, $P2X_2$, $P2X_3$ and $P2X_7$.

Preferably detection of P2X receptor expression profile is by immunohistochemical means. It will be clear to the skilled addressee that the P2X

receptors may be detected by other means including ELISA, RIA or similar immunological techniques, depending on the source of the cell or tissue sample and the reagents available. Preferably, the P2X receptors are detected by a colorimetric assay. It will also be clear to those skilled in the art that Western blotting techniques and detection of P2X purinergic receptor mRNA may be useful in determining the P2X receptor expression profile.

In the context of the present invention, the term "pre-neoplastic cells" comprises cells that are hyperplastic or hypertrophic.

In the context of the present invention the term "suite of antibodies" comprises polyclonal antibodies which contain several different antibodies specific for the same or different antigens and which are able to specifically differentiate between each of the P2X receptor subtypes. When the antibodies are monoclonal, the term "suite of antibodies" also comprises a panel of antibodies able to specifically differentiate between each of the P2X receptor subtypes.

In the context of the present invention, detection of an "expression profile" comprises detection of a pattern or intensity of expression.

Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

BRIEF DESCRIPTION OF FIGURES

Figure 1 shows an example of the level of $P2X_1$ labelling in a biopsy sample taken from a normal human prostate (left) and from a patient with advanced prostate cancer (right).

Figure 2 shows a comparison of prostate epithelium (E) from a young (12 week) rat (left), and tissue from an aged rat (18 months; right). The aged tissue shows marked hyperplasia.

Figure 3 shows an example of $P2X_1$ labelling in normal breast (right) and of the substantial down-regulation in breast tumour tissue (left).

Figures 4a, b, d and e show core biopsies from a 71-year old man with increasing PSA. Diagnosis - BPH. The H&E stain (4a) shows mild hyperplasia in the apical epithelium (arrow) of the prostatic acini (A). Figure 4d is a high-power micrograph of this area (arrow). Labelling with anti-P2X in the same area (4b) shows the complete de-expression of P2X receptors that is characteristic of BPH (4b-arrow). Figure 4e is a high-power micrograph of this area showing complete P2X de-expression in the mildly hyperplasic epithelium (4e-arrow). Figure 4c. Section of core biopsy from a 69-year old man. PSA unknown. This case was also diagnosed as BPH by H&E stain (not shown) but features distinctive Stage 1 P2X labelling, as characterised by prominent epithelial nuclei (PEN) (4c-arrow). Figure 4f is a high-power micrograph of these densely-labelled nuclei (4f-arrow), as shown in Figure 4c. Figures 4a and 4d, H&E stain. Figures 4b, c, e and f, anti-P2X immunoperoxidase label. No counterstain. Bar for low power micrographs (4a, b and c) is 1cm = 150 μm. Bar for high power micrographs (4d, e and f) is 1 cm = 40 μm.

Figures 5a-c show core biopsies (supplied as 3 cores) from a 57-year old man with increasing PSA. Two cores were diagnosed as containing areas of BPH adjacent to areas of advanced cancer, Gleason score 8. Figure 5a shows an area of BPH with no cancerous markers (5a-arrow) stained with H&E. Figure 5b is a serial section from the same block labelled with $P2X_1$ antibody. The P2X labelling is characteristic of

translocation Stage 2. The presence of these features, in tissue diagnosed by H&E staining as BPH, indicates not only the presence of preneoplastic change but that those changes are more advanced. Figure 5c is a high-power micrograph from a serial section of the acinus arrowed in Figure 5b. It depicts Stage 2 features as follows: some PEN remains (N-arrowhead) but most labelling is now punctate and cytoplasmic (P-arrow). Previous experiments have shown that each puncta is an individually-labelled P2X receptor or small localised patch of receptors. The lateral plasma membranes are clearly labelled (L-arrow) and there is labelling in the apical epithelium (A-arrow).

Figures 5d-f show a core biopsy (3 cores) from an 81-year old man with a PSA of 8.1. In this case the diagnosis was infiltrating adenocarcinoma, Gleason score 6. H&E staining (Figure 5d) showed areas of both BPH and invasive cancer (prominent nucleoli, basement membrane invasion and abnormal acinal architecture). Figure 5e shows an increase in P2X labelling in the apical epithelum (arrow) but a general decrease in overall signal. A high-power micrograph (Figure 5f) shows these P2X labelling features to be typical of P2X translocation Stage 3. The labelling is less intense than that seen in Stage 2 (Figure 5b), due to a concentration of label in the apical epithelium. The nuclei are devoid of label except for the nuclear membrane (N-arrow). The label is homogeneous rather than punctate, and is mostly found on the apical epithelium (A-arrow). At the completion of the translocation process, P2X label was commonly concentrated in the apical epithelium after which it was de-expressed (D). Figures 5a and 5d, H&E stain. Figures 5b, c, e and f, P2X immunoperoxidase label. No counterstain. Bar for low power micrographs (5a, b, d and e) is 1cm = 150 μm. Bar for high power micrographs (5c and f) is 1 cm = 40 μm.

Figures 6a-m show staining patterns in breast cancer biopsy tissue compared with normal tissue.

DESCRIPTION OF THE INVENTION

A preferred embodiment of the invention will now be described by way of example only and with reference to the accompanying Figures.

Example 1 - Immunohistochemical Procedure

The immunohistochemical method used in this study was adapted from Barclay [31]. Sections with a thickness of 8 μm were cut from unfixed, frozen tissue using a Reichert Jung 2800 Frigocut cryotome. Sections were air dried at room temperature for 1 hour, fixed for 12 hours in acetone at -20°C and air dried at room temperature for 1 hour prior to antibody labelling. They were then incubated at room temperature with one of either rabbit or sheep anti-$P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$ antibody. After washing, sections were then incubated in the secondary antibody; a 1:30 dilution of HRP-conjugated goat anti-rabbit secondary antibody (Dako) for 30 mins for rabbit primaries and HRP-conjugated goat anti-sheep secondary antibody (Dako) for sheep primaries. Slides were again rinsed and then immersed in 15% diaminobenzidine tetrahydrochloride (DAB - Sigma) for 10 minutes. Sections were rinsed, air dried and mounted in DPX (Merck). Control slides were incubated in diluent buffer during the first incubation and then treated in the same manner as the experimental slides. Negative control slides were treated in the same manner as the experimental slides except that the primary antibody was replaced with non-immune serum.

Example 2 - Antibody Production

The consensus sequences of the rat $P2X_1$ [32], $P2X_2$ [33], $P2X_3$ [34], rat $P2X_4$ [35], rat $P2X_5$ [36], rat $P2X_6$ [36], rat $P2X_7$ [37], human $P2X_7$ [38], human $P2X_1$ [39], human $P2X_3$, [40], human $P2X_4$ [41] and human $P2X_5$ [42] cloned receptors were examined for suitable epitopes following the approach adopted in Hansen et al. [15]. The non-homologous epitopes corresponding to the segment Lys199-Cys217 used in rat $P2X_1$ were utilised in rat $P2X_3$, rat $P2X_6$ and rat $P2X_7$. Variations were applied to rat $P2X_4$ which used the sequence Ile235-Gly251 to which was attached a C-terminal Cys residue for cross-linking to a 6 kDa diphtheria toxin domain. The $P2X_2$ epitope was selected from a region within the C1 domain [15], Cys130-Gly153. The rat $P2X_5$ epitope was selected from a region closer to the second transmembrane domain but still extracellular (Lys314-Ile333 to which was added a C-terminal Cys also for conjugation). Although largely homologous with rat $P2X_4$, cross-labelling of $P2X_4$ and $P2X_5$ did not occur. All antibodies against rat sequences were able to label corresponding human receptors. A separate epitope was used for the human $P2X_1$ and $P2X_7$ sequences. This was taken just C-terminal to the first transmembrane domain from Lys68-Val84 with an N-terminal Cys added for conjugation via a diphtheria toxin domain using maleimidocaproyl-N-hydroxysuccinimide. The epitope for human $P2X_3$ antibody was the equivalent sequence used for rat, while the epitopes for human $P2X_4$ and human $P2X_5$ were Cys270-Asn287 and Cys272-Ser288 respectively. All syntheses were carried out using standard t-BOC chemistry on an ABI synthesiser [43]. The peptide-antigen conjugates were suspended in water at 5 mg/mL and aliquots emulsified by mixing with Complete Freund's Adjuvant.

Emulsion volumes of 1 mL containing 2 mg of peptide were injected intramuscularly with second, third, fourth and fifth immunisations followed at 2 week intervals using Incomplete Freund's Adjuvant. Final bleeds via venepuncture were obtained at 10-12 weeks, after it was established that adequate antibody titres had been obtained in the rabbits or sheep used for each epitope. The blood was incubated at 37°C for 30 min, and stored at 4°C for 15 h after which the serum was collected following centrifugation and stored at -20°C in small aliquots. Sera were tested with an ELISA assay for antibodies specific for each peptide [15]. The antibody titre, defined as the reciprocal of the serum dilution resulting in an absorbance of 1.0 above background in the ELISA assay, was in the range 75,000±4,000 compared with 225±25 for the pre-immune samples.

Affinity purification of each of the antibodies against the specific epitope for that antibody resulted in reduced background but identical labelling trends.

Example 3 - Specificity of antibodies

Each of the P2X antisera used has been shown to possess similar distributions in many cases but with distinctly different distributions in other cases indicating that the antisera do not lack specificity. Specificity was demonstrated by affinity purification of the sera against the cognate peptides. To further verify antibody specificity, individual antibody such as the antibody to $P2X_1$ was added to cells transfected with the corresponding $P2X_1$ cDNA in the presence and absence of a 10mM concentration of the $P2X_1$ epitope. Immunolabelling and confocal imaging of the tranfected *Xenopus* oocytes demonstrated that the expressed $P2X_1$ is located, as expected, within the cell membrane and the presence of a 10mM concentration of the

cognate peptide as an absorption control resulted in the blocking of $P2X_1$ staining [18].

Individual specificity of all other antibodies has been similarly demonstrated.

Example 4 - Preparation of tissue for ultrastructural examination of morphology

Tissue was processed for morphological examination as follows: sections of approximately 3mm X 3mm in size were fixed in 2.5% glutaraldehyde in 0.1M Tris buffer pH 7.2 for 1 hour. They were then washed and post fixed in 2% aqueous osmium tetroxide for 2 hours. After further washing, the tissue was dehydrated in a graded series of alcohols and embedded in Spurr's resin. Curing was carried out at 50^0C for 18 hours. 100nm sections were then cut with a diamond knife, stained with uranyl acetate and Reynolds lead citrate in the usual manner and examined in a Phillips 400 transmission electron microscope.

Example 5 - Ultrastructural Immunocytochemistry

The method of Slater [44] was used. In short, thin sections (100nm) were cut and retrieved on 300 mesh nickel grids. After incubation in blocking solution (1% BSA in PBS) for 30 min, the sections were placed on the surface of a drop of the blocking solution (with the addition of 0.05% Tween 20) containing HRP-conjugated goat anti-rabbit secondary antibody or HRP-conjugated goat anti-sheep secondary antibody (diluted 1:100) for 1 h at room temperature. Grids were then rinsed three times for 10 min in PBS and placed on drops of goat anti-rabbit secondary antibody conjugated to 10 nm gold (Nanoprobe) for 1 h at room temperature. The grids were then washed twice with PBS followed by one wash with distilled water, for 10 min each and then placed in the vapour of 2% aqueous osmium tetroxide for 1 minute. Sections were then stained with aqueous uranyl acetate solution for 20 min, lead

citrate for 10 min, rinsed twice for 10 min in distilled water and examined with a Phillips 400 electron microscope at 80 kV.

Example 6 – P2X receptors in human cancer tissue

In a study of 4 normal and 6 human prostate cancer cases, $P2X_1$, $P2X_3$, and $P2X_4$ subtypes were markedly increased in human prostate cancer tissue. There was no labelling at all for these subtypes in normal tissue. The labelling patterns for $P2X_1$ (Figure 1) in the cancerous tissue were particularly interesting in that there was a greater proportion of labelled acinar epithelial cells with each stage of prostate disease, suggesting a direct correlation between neoplastic transformation and the extent of $P2X_1$ acinar labelling. $P2X_5$ was also increased in some prostate cancer cells (results not shown). There was very little or no labelling for $P2X_5$ in normal tissue.

Example 7 – P2X receptors, growth, innervation, and metabolic factors, ionic calcium modulation in young vs aged Wistar rats

P2X receptors and apoptosis:

Studies comparing prostates from four 12 week-old rats and four 1.5 year-old rats resulted in the detection of a marked increase in epithelial hyperplasia in the aged rats, resembling BPH in humans (Figure 2). As with the human cancer tissue, $P2X_1$, $P2X_3$, and $P2X_4$ receptors and tyrosine kinase A receptor antibody were up-regulated in the prostatic epithelium of aged rats, when compared with that of young rats. As previously discussed, this indicates an increase in protein phosphorylation (activation), DNA synthesis, intracellular microtubule expression (organelle transport), up-regulation of adjacent receptors for other neurotransmitters, cell proliferation and an influx of ions (primarily ionic calcium) into the epithelial cells

indicating apoptosis. An increase in alpha (1B) (voltage-gated calcium channel), and a reduction in the calcium-regulating hormone stanniocalcin was also observed in the aged rat prostates. PDGF and IGF-1 both inhibit apoptosis and were decreased in the aged rats [45]. Thus, the aged rat prostate undergoes apoptosis and similar changes in P2X receptor expression as human prostate cancer tissue, and therefore may be used to investigate prostate cancer aetiology.

Innervation, other receptors and metabolic factors:

In the aged rats, there was an increase in microtubular structures in the fibromuscular septa subjacent to the prostatic epithelium. These structures appeared similar in micrographs depicting the apoptosis-associated purinergic receptors $P2X_1$, $P2X_7$, ionic calcium, and the innervation factors VAMP, muscarinic receptor (M2), SV-2, SNAP-25, S100, and transferrin receptor, all of which were up-regulated in the aged rats. Alpha (1B) voltage-gated calcium channels and tyrosine kinase A receptors were also up-regulated in the aged rats. Stanniocalcin was down-regulated while the $P2X_1$ and $P2X_7$ apoptotic calcium channel receptors were up-regulated. These data indicate an increase of calcium ion inflow, metabolic rate, microtubule transport and innervation of the prostatic epithelium in the aged rats, and also suggest that this model could be used to investigate human prostate cancer.

Example 8 - Breast cancer cell lines

In 6 breast cancer cell lines supplied as frozen sections, $P2X_1$, $P2X_3$, and $P2X_4$ purinergic subtypes were labelled using the same techniques employed in the labelling of prostate tissues. The labelling pattern (Figure 3) was suggestive of the labelling patterns seen in both human prostate cancer tissue (Figure 1) and the prostate of the male aged Wistar rat (Figure 2).

Example 9 - Prostate cancer diagnoses (Figures 4a-f and 5a-f)

The expression characteristics of the purinergic receptor calcium channels ($P2X_{1-7}$) were examined in normal and pathological prostate tissue from 65 cases representing each stage of prostate disease: normal, BPH, preneoplastic and cancerous (Gleason's grade 5-9). Clear translocation features were noted in tissue labelled with $P2X_1$, $P2X_2$, $P2X_3$ and $P2X_7$. After a lengthy process of optimisation and standardisation of P2X antibody production and labelling protocols, a standardised protocol was developed. A mixture of $P2X_1$, $P2X_2$, $P2X_3$ and $PX2_7$ subtypes at a concentration of 0.5 μg / mL IgG each, diluted 1:100 with PBS, proved to be the best reagent for demonstrating the translocation features described. $P2X_4$, $P2X_5$ or $P2X_6$ labelling was of lesser significance. Using this reagent to label tissue sections from each category of prostate cancer it was found that there was a sequential expression and translocation of P2X labelling from the nuclei to the cytoplasm and lateral plasma membranes, ultimately expressing primarily in the apical epithelium, as cancer progressed (Figs 4f, 5c, 5f).

P2X labelling was completely de-expressed in BPH tissue (Figs 4b, 4e). Preneoplastic P2X translocation occurred in three distinct stages. Stage 1 was characterised by dense, prominent P2X-labelled epithelial nuclei (PEN) on a pale background (Figs 4c, 4f). Stage 2 featured a progressive de-expression of PEN and the appearance of dense and markedly punctate cytoplasmic labelling, nuclear membrane and lateral plasma membrane labelling, and an increasing signal on the apical epithelium (Figs 5b, 5c). Stage 3 was represented by nuclei labelled only on the nuclear membrane (NO), no cytoplasmic signal, homogeneous rather than punctate labelling, and a dense label in the apical epithelium (Figs 5e, 5f).

In the present study, 56% of cases diagnosed as normal or BPH by haematoxylin and eosin (H&E) staining, showed Stage 1 or Stage 2 P2X labelling. The remaining cases, ranging from Gleason score G5 to G9, had P2X Stage 2 or 3 labelling features. Stage 3 labelling was always accompanied by the histological features of cancer (Fig 5e). True non-neoplastic BPH tissue was easily distinguished by the complete de-expression of all P2X subtypes in the epithelium and stroma. We propose that biopsy tissue that has been histologically diagnosed as normal but displays P2X labelling features, may be in the process of early (preneoplastic) transformation at a metabolic level. The demonstration of Stage 2 features in 'normal' tissue suggests that the preneoplastic process is more advanced in that tissue. The P2X labelling features described are stage-specific and uniform throughout the entire area of cells representative of each histological classification. In cores that contained both BPH and cancer areas, P2X labelling was clearly and uniformly demarcated into either BPH or one of the cancer labelling patterns. It is proposed that this technique can be used to exclude (and reassure) patients with non-neoplastic prostatic conditions from those with early cancer and also identify rapidly-developing preneoplasia, that may lead to malignancy. This information may permit earlier and more accurate treatment decisions.

Example 10 - Breast cancer diagnoses

Subtypes $P2X_2$, $P2X_3$, and $P2X_7$ are significantly down-regulated in breast cancer biopsy tissue compared with normal. Subtypes $P2X_1$, $P2X_4$, $P2X_5$ and $P2X_6$ were unlabeled in both the normal and cancerous tissue. Tissue was pre-incubated with 3% hydrogen peroxide and 5% horse serum to suppress endogenous peroxidase activity. Examples of the staining patterns are shown in Figs 6a-m.

Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.

References

1. Lian FR, Bhuiyan M, Li YW, Wall N, Kraut M, and Sarkar FH, 1998 Genistein-Induced G(2)-M Arrest, P21(Waf1) Upregulation, and Apoptosis in a Non-Small-Cell Lung Cancer Cell Line. Nutr. & Cancer. 31:184-191.

2. Hoey J, 1998 Prostate cancer: progress and perplexity. CMAJ 159:1-3.

3. Kolonel LN, Nomura AM, Hinds MW, Hirohata T, Hankin JH, and Lee J, 1983 Role of diet in cancer incidence in Hawaii. Cancer Res. 43:2397s-2402s.

4. Festuccia C, Vincentini C, di Pasquale AB, Aceto G, Zazzeroni F, Miano L, and Bologna M, 1995 Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol. Res. 7:131-138.

5. Saxena S, Mohanty NK, and Jain AK, 1997 Screening of prostate cancer in males with prostatism. Ind. J. Pathol. Micro. 40:441-450.

6. Diamandis EP and Yu H, 1997 Nonprostatic sources of prostate-specific antigen. Urol. Clin. Nth. Am. 24:275-282.

7. Weyler J, 1999 Prostate cancer: screening or watchful waiting? Ann. Oncol. 9:9-11.

8. Bassler TJ, Orozco R, Bassler IC, Odowd GJ, and Stamey TA, 1998 Most Prostate Cancers Missed By Raising the Upper Limit of Normal Prostate-Specific Antigen For Men in Their Sixties Are Clinically Significant. Urol. 52:1064-1069.

9. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, and Fair WR, 1998 Incidence and clinical significance of false-negative sextant prostate biopsies. J. Urol. 159:1247-1250.

10. Gao X, Porter AT, Grignon DJ, Pontes JE, and Honn KV, 1997 Diagnostic and prognostic markers for human prostate cancer. Prostate 31:264-281.

11. Small EJ, 1997 Prostate cancer. Curr. Opin. Oncol. 9:277-286.

12. Moul JW, Mooneyhan RM, Kao TC, McLeod DG, and Cruess DF, 1998 Preoperative and Operative Factors to Predict Incontinence, Impotence and Stricture After Radical Prostatectomy. Prost. Can. & Prost. Dis. 1:242-249.

13. Drury A and Szent-Gyorgyi A, 1929 The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. 68:213-237.

14. Abbracchio M and Burnstock G, 1998 Purinergic signalling: pathophysiological roles. Jap. J. Pharmacol. 78:113-145.

15. Hansen MA, Barden JA, Balcar VJ, Keay KA, and Bennett MR, 1997 Structural motif and characteristics of the extracellular domain of P2X receptors. Biochem. Biophys. Res. Comm. 236:670-675.

16. Hansen MA, Balcar VJ, Barden JA, and Bennett MR, 1998 The distribution of single P2X1-receptor clusters on smooth muscle in relation to nerve varicosities in the rat urinary bladder. J. Neurocytol. 27:529-539.

17. Hansen M, Dutton J, Balcar V, Barden J, and Bennett M, 1999 P2x (purinergic) receptor distributions in rat blood vessels. J. Auton. Nerv. Syst. 75:147-155.

18. Dutton J, Hansen M, Balcar V, Barden J, and Bennett MR, 1998 Development of P2X receptor clusters on smooth muscle cells in relation to nerve varicosities in the rat urinary bladder. J. Neurocytol. in press.

19. Filipovic DM, Adebanjo OA, Zaidi M, and Reeves WB, 1998 Functional and molecular evidence for P2x receptors in Llc-Pk1 Cells. Am. J. Physiol. 43:F1070-F1077.

20. Abbracchio M, 1996 P1 and P2 receptors in cell growth and differentiation. Drug. Dev. Res. 39:393-406.

21. Augustine G, Betz H, Bommert K, Charlton M, DeBello W, Hans M, and Swandulla D, Molecular pathways for presynaptic calcium signalling, in Molecular and Cellular Mechanisms of Neurotransmitter Release, L. Stjarne, *et al.*, Editors. 1994, Raven Press: New York. p. 139-155.

22. Di Firgilio F, Pizzo P, Zanovello P, Bronte V, and Collavo D, 1990 Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Immunol. Today 11:274-277.

23. Siems W, Grune T, Schmidt H, Tikhonov Y, and Pimenov A, 1993 Purine nucleotide levels in host tissues of Ehrlich ascities tumor-bearing mice in different growth phases of the tumor. Cancer Res. 53:5143-5147.

24. Natori Y, Moriguchi M, Fujiwara S, Takeshita I, Fukui M, Iwaki T, and Kanaide H, 1992 Effects of L-NMMA and L-NNA on the selective ATP-induced enhancement of intratumoral blood flow. J. Cereb. Blood Flow Metab. 12:120-127.

25. Figueroa JP and Massmann GA, 1995 Estrogen increases nitric oxide synthase activity in the uterus of nonpregnant sheep. Am. J. Obstet. Gynecol. 173:1539-1545.

26. Rabbani SA and Xing RH, 1998 Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. 12:911-920.

27. Ciccarelli R, Di Iorio P, Ballerini P, Ambrosini G, Giuliani P, Tibone G, and Caciagli F, 1994 Effects of exogenous ATP and related analogues on the proliferation rate of dissociated primary cultures of rat astrocytes. J. Neurosci. Res. 39:556-566.

28. Potter SW, Gaza G, and Morris JE, 1996 Estradiol induces E-cadherin degradation in mouse uterine epithelium during the estrous cycle and early pregnancy. J. Cell. Physiol. 169:1-14.

29. Kedeshian P, Sternlicht MD, Nguyen M, Shao ZM, and Barsky SH, 1998 Humatrix, a Novel Myoepithelial Matrical Gel With Unique Biochemical and Biological Properties. Cancer Lett. 123:215-226.

30. Dethlefsen SM, Raab G, Moses MA, Adam RM, Klagsbrun M, and Freeman MR, 1998 Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J. Cell. Biochem. 69:143-153.

31. Barclay A, 1981 The localisation of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues. Immunology 42:593-600.

32. Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, and Buell G, 1994 A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP [see comments]. Nature 371:516-519.

33. Brake AJ, Wagenbach MJ, and Julius D, 1994 New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature 371:519-523.

34. Lewis C, Neidhart S, Holy C, North RA, Buell G, and Surprenant A, 1995 Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons [see comments]. Nature 377:432-435.

35. Buell G, Collo G, and Rassendren F, 1996 P2X receptors: an emerging channel family. Eur. J. Neurosci. 8:2221-2228.

36. Collo G, North RA, Kawashima E, Merlo-Pich E, Neidhart S, Surprenant A, and Buell G, 1996 Cloning OF P2X5 and P2X6 receptors and the distribution and

properties of an extended family of ATP-gated ion channels. J. Neurosci. 16:2495-2507.

37. Surprenant A, Rassendren F, Kawashima E, North RA, and Buell GS, 735-738., 1996 The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272:735-738.

38. Rassendren F, Buell GN, Virginio C, Collo G, North RA, and Surprenant A, 1997 The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J. Biol. Chem. 272:5482-5486.

39. Longhurst PA, Schwegel T, Folander K, and Swanson R, 1996 The human P2x1 receptor: molecular cloning, tissue distribution, and localization to chromosome 17. Biochim. Biophys. Acta 1308:185-188.

40. Garcia-Guzman M, Stuhmer W and Soto F, 1997 Molecular characterization and pharmacological properties of the human P2X3 purinoceptor Brain Res. Mol. Brain Res. 47, 59-66.

41. Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund PE, and Stuhmer W, 1997 Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol. Pharmacol. 51, 109-118.

42. Le KT, Paquet M, Nouel D, Babinski K and Seguela P, 1997 Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system FEBS Lett. 418, 195-199.

43. Barden JA, Cuthbertson RM, Jia-Zhen W, Moseley JM, and Kemp BE, 1997 Solution structure of parathyroid hormone related protein (residues 1-34) containing an Ala substituted for an Ile in position 15 (PTHrP[Ala15]-(1-34)). J. Biol. Chem. 272:29572-29578.

44. Slater M, Patava J, Kingham K, and Mason RS, 1994 Modulation of growth factor incorporation into the extracellular matrix of human osteoblast-like cells in vitro by 17β estradiol. Am. J. Physiol. 267:E990-E1001.

45. Kiess W and Gallaher B, 1998 Hormonal control of programmed cell death/apoptosis. Eur. J. Endocrinol. 138:482-491.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method of staging and/or diagnosing pre-neoplastic and/or neoplastic states in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from said mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

2. A method of determining the aetiology of carcinogenesis in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

3. A method according to claim 1 or claim 2 wherein the mammal is a human.

4. A method according to any one of claims 1 to 3 wherein the cells are prostate tissue cells.

5. A method according to any one of claims 1 to 3 wherein the cells are breast tissue cells.

6. A method according to any one of claims 1 to 5 wherein the cells are obtained by biopsy.

7. A method according to any one of claims 1 to 4 wherein the cells are obtained from digital rectal examination exudate and/or semen.

8. A method according to any one of claims 1 to 3 wherein the cells are obtained from a body fluid.

9. A method according to any one of claims 1 to 8 wherein detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent.

10. A method according to claim 9 wherein the P2X antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

11. A method according to claim 10 wherein the antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$ or $P2X_7$.

12. A method of diagnosing prostate cancer in a subject, comprising detecting the expression profile of $P2X_1$, $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in prostate cells and/or tissue from the subject using $P2X_1$, $P2X_2$, $P2X_3$ and/or $P2X_7$ antibody respectively, wherein an increase in the intensity of the P2X purinergic receptor expression profile in the prostate cells and/or tissue, compared to the expression profile of prostate cells and/or tissue from a prostate having benign prostate hyperplasia, is diagnostic of the presence of prostate cancer.

13. A method of diagnosing breast cancer in a subject comprising detecting the expression profile of $P2X_2$, $P2X_3$, and/or $P2X_7$ purinergic receptors in breast cells and/or tissue from the subject using $P2X_2$, $P2X_3$, and/or $P2X_7$ antibody respectively, wherein a decrease in the intensity of the P2X purinergic receptor expression profile in the breast cells and/or tissue compared to the expression profile of breast cells and/or tissue from the breast of a normal subject, is diagnostic of the presence of breast cancer.

14. A method according to any one of claims 9 to 13 wherein the antibody reagent comprises a polyclonal antiserum.

15. A method according to any one of claims 9 to 13 wherein the antibody reagent comprises a monoclonal antiserum.

16. A method according to any one of claims 9 to 14, wherein the antibody reagent is a suite of polyclonal antibodies.

17. A method according to any one of claims 9 to 13 or 15, wherein the antibody reagent is a suite of monoclonal antibodies.

18. A method according to claim 16 or claim 17 wherein the suite of P2X receptor antibodies comprises a combination of the P2X receptor sub-types antibodies.

19. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by immunohistochemical means.

20. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by ELISA.

21. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by RIA.

22. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by Western blot.

23. A method according to any one of claims 1 to 18 wherein detection of the P2X purinergic receptor expression is by detection of P2X purinergic receptor mRNA.

24. Use of a P2X purinergic receptor antibody reagent to stage and/or diagnose a pre-neoplastic and/or neoplastic state in a mammalian subject.

25. Use of a P2X purinergic receptor antibody reagent to determine the aetiology of carcinogenesis in a mammalian subject.

26. Use according to claim 24 or claim 25 wherein the mammal is a human.

27. Use according to any one of claims 24 to 26 wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.

28. Use according to any one of claims 24 to 26 wherein the P2X purinergic receptor antibody is a monoclonal antiserum.

29. Use according to claim 27 or claim 28 wherein the P2X purinergic receptor antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

30. Use according to claim 29 wherein the P2X purinergic receptor antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$ or $P2X_7$.

31. Use according to any one of claims 26 to 27 or 29 and 30, wherein the P2X purinergic receptor antibody reagent is a suite of polyclonal antibodies.

32. Use according to any one of claims 24 to 26 or 28 to 30, wherein the P2X purinergic receptor antibody reagent is a suite of monoclonal antibodies.

33. Use according to claim 31 or claim 32 wherein the suite of P2X receptor antibodies comprises a combination of antibodies specific for $P2X_1$, $P2X_2$, $P2X_3$ and $P2X_7$.

34. An isolated mammalian cell or tissue sample complexed with a P2X purinergic receptor-specific antibody reagent.

35. An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor-specific antibody reagent comprises polyclonal antiserum.

36. An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor antibody reagent comprises monoclonal antiserum.

37. An isolated mammalian cell or tissue sample according to claim 35 or claim 36 wherein the P2X purinergic receptor-specific antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

38. An isolated mammalian cell or tissue sample according to claim 37 wherein the P2X purinergic receptor-specific antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, or $P2X_7$.

39. A kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising means for detection of P2X purinergic receptor expression profile in a

sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.

40. A kit according to claim 39 wherein the detection means comprises an antibody reagent specific for a P2X purinergic receptor.

41. A kit according to claim 40 wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.

42. A kit according to claim 40 wherein the P2X purinergic receptor antibody reagent comprises a monoclonal antiserum.

43. A kit according to claim 42 wherein the P2X purinergic receptor antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

44. A kit according to claim 43 wherein the antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, or $P2X_7$.

45. A kit according to any one of claims 39 to 44 wherein the P2X purinergic receptor expression profile is detected by a colorimetric assay.

46. A kit according to claim 45 wherein the assay is an ELISA.

47. A kit according to claim 45 wherein the assay is an RIA.

48. A kit according to any one of claims 39 to 47 wherein the sample is a body fluid.

49. A kit according to any one of claims 39 to 47 wherein the sample is a digital rectal examination exudate.

50. A kit according to any one of claims 39 to 48 wherein the sample is a biopsy sample.

51. An antibody reagent specific for a P2X purinergic receptor, wherein the reagent is capable of differentiating between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

52. An antibody reagent specific for a P2X purinergic receptor when used to differentiate between functional and non-functional P2X receptors in cells and/or tissue.

53. An antibody reagent according to claim 51 or claim 52 wherein the antibody reagent comprises a polyclonal antiserum.

54. An antibody reagent according to claim 51 or claim 52 wherein the antibody reagent comprises a monoclonal antiserum.

55. An antibody reagent according to any one of claims 51 to 54 wherein the P2X antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, $P2X_4$, $P2X_5$, $P2X_6$ or $P2X_7$.

56. An antibody reagent according to claim 55 wherein the antibody reagent is specific for $P2X_1$, $P2X_2$, $P2X_3$, or $P2X_7$.

Fig 1

The following figure shows an example of the level of P2X1 labeling in a biopsy sample taken from a normal human prostate (left) and from a patient with advanced prostate cancer (right).

Normal Prostate **Prostate Cancer**

Fig 2

The following Figure shows that, compared with prostate epithelium (E) from a young (12 week) rat (left), tissue from an aged rat (18 months) shows marked hyperplasia (right).



Fig 3

The following figure shows an example of P2X1 labeling in normal breast (right) and a substantial down-regulation in breast tumour tissue (left).



Fig 4

Fig 5

Fig 6



(a) Low Power: normal tissue, P2X2 label.

Bars - 50μm.

(b) Low Power: breast cancer, P2x2.



(c) Low Power: normal tissue, H&E stain.

Bars = 50μm.

(d) Low Power: breast cancer, H&E stain.

Fig 6



(e) High Power: normal tissue, H&E stain. (f) High Power: breast cancer, H&E stain.

(g) High Power: normal tissue, P2x2 label. (h) High Power: cancer tissue, P2x2 label.

Fig 6



(i) High Power: normal tissue, P2x3 label.

(j) High Power: cancer tissue, P2x3 label.

(k) High Power: normal tissue, P2x7 label.

(l) High Power: cancer tissue, P2x7 label.

Bars 20 µm. Arrow = epithelial acinus.

Bars = 20µm. Arrows = epithelial acinus.



(m) Control: normal tissue, bar = 50 µm, erythrocytes with residual endogenase activity (arrow)

Fig 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00363

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. [7]: G01N 33/574

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Chem. Abs., WPIDS, Medline: purinergic recepetors, sarcoma, neoplasm, cancer, tumour, tumor, purinergic ion channel, P2X, marker, profile, expression, diagnosis

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Nawa, G., *et al* , 1999. BRITISH JOURNAL OF CANCER, **80(8):** 1185-89. Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours. - see whole document	1
X	Wurl, P., *et al* , 1998. ONCOGENE, **16(9):** 1183-85. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. - see whole document	1

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
21 July 2000

Date of mailing of the international search report
15 / 08 / 00

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaustralia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

ISOBEL TYSON
Telephone No : (02) 6283 2563

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00363

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AU 64184/98 (OTSUKA PHARMACEUTICAL CO., LTD.), 20 October 1998 - see abstract	1
A	Urano, T. *et al* , 1997. CANCER RESEARCH, 57: 3281-87. Cloning of P2XM, a novel human P2X receptor gene regulated by p53. - see whole document	1
A	Höpfner, M., *et al* , 1998. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 251: 811-17. Expression of functional P_2-purinergic receptors in primary cultures of human colorectal carcinoma cells. - see whole document	1

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00363

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
AU	64184/98	WO	9842835	EP	1006186	JP	10262681

END OF ANNEX